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This thesis describes in detail the methodology
involved in developing a solid phase radioimmunoassay
for progesterone in human plasma as well as some
applications.
The introduction reviews progesterone as a
hormone involved in reproduction and describes its role
in the normal menstrual cycle, in pregnancy and traces
briefly the important steps in the history of its
measurement in the human blood.
Hemisuccinate derivatives of llOy-hydroxyprogesterone
and 6 ,6 -hydroxyprogesterone have been prepared and
conjugated to bovine serum albumin by the mixed
anhydride reaction. Antisera in 8 of the 12 rabbits
gave usable dilutions of 1/50000 or more. The average
affinity constants of the three selected antisera to
9 9
llo(. -hydroxyprogesterone-BSA are 3.15 x 10 , 3.77 x 10
9
and 3.92 x 10 l/M and those of three selected antisera
9 9
to 6 (3-hydroxyprogesterone-BSA are 2.92 x 10 , 3.55 x 10
g
and 3.92 x 10 l/M. Maximum assay sensitivities wxth
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antisera were generally obtained after 3-7 months from
primary immunization and remained unchanged thereafter
following further booster injections.
Extensive studies on the specificity of the
antisera have been carried out and discussed. Cross
reaction studies of 8 compounds with selected antisera
to llX-hydxoxyprogesterone-BSA showed little alteration
in their specificities following booster injections over
long periods.
The routine procedure is based upon the use of an
antiserum to 11C< -hydroxyprogesterone-BSA which is
covalently linked to microcrystalline cellulose} the
double antibody method being used as a reference system.
In the extraction procedure ethanol is first added to the
plasma (10 Vol. plasma + 1 Vol, ethanol) after which a
single extraction with light petroleum yields a constant
recovery 92.4 _+ 1.2 (S.D.) % of added [^^progesterone
and obviates the need for tracer recoveries on each
sample being assayed. The effect of the solvent residues
on the assay has been investigated and distortions of the
response curve due to this have been almost eliminated.
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A 200^j! plasma sample is sufficient for the measurement
of progesterone at all stages of the menstrual cycle.
Other reliability criteria, accuracy precision,
specificity and sensitivity have been shown to be
satisfactorily met.
The method has been applied for assaying the
hormone in the urine of the normally menstruating women.
The behaviour of unextracted plasma in the assay
has been briefly investigated because the specificity
of the antisera to known steroids appeared, to permit
such assays at least for the limited but important
purpose of monitoring luteal function. However, grossly
high and unacceptable values were obtained when such
assays were performed.
The following physiological situations have been
studied:
Progesteroneklevels have been measured in daily
samples throughout a single menstrual cycle from five women.
The first detectable rise of progesterone is recorded only
after the start of the midcycle rise of luteinizing hormone.
Effect /
4
Effect of ACTH stimulation and dexamethasone
suppression on progesterone levels has been studied in
males. A four-fold but slow rise over 6 hours in response
to ACTH suggests a slow rate of synthesis in the adrenals.
Progesterone was still detectable in plasma from normal
men during dexamethazone suppression,,
Studies from frequent blood sampling over a 6 h
period in three males showed no evidence of a regular
pattern of episodic secretion of progesterone. No
relationship was observed between the secretory patterns
of progesterone and those of luteinizing hormone and
testosterone which were measured in the same blood samples.
(The method for measuring progesterone as described
in this thesis has been published as "A solid-phase
Radioimmunoassay for Plasma Progesterone"; Dighe K„K.
and WoM. Hunter (1974), Biochem. J„ 143, 219 - 231).







The corpus luteum of ovary finds its first recorded
mention in 1672 (de Graff, 1672). Its function as an organ
of internal secretion in the maintenance of pregnancy was
proposed by Prenent (1898). Continued interest in the organ
culminated in the publication of the first significant evidence
of the biological importance of its secretion when it was
demonstrated that corpus luteum extracts from the sow were able
to maintain pregnancy in castrated rabbits (Corner and Allen,
1929). Improved techniques led to the isolation of the hormone
responsible for this effect from corpora lutea of several species.
Elucidation of its structure followed and the name progesterone
was proposed (Butendant, et al., 1934).
Progesterone, pregn-4~ene~3, 20-dione has an empirical
formula for C H o and molecular weight of 314.4. It is the3 X 30 3
least polar of all the naturally occurring steroids, its
solubility in water being low, while it dissolves readily in
organic solvents. It is synthesized from cholest.ffV'ol j
pregnenolone - their sulphates, and from acetate, and is one
of the key intermediates in the biosynthesis of steroids on
. 4
the J\ - pathway in the ovary, testis and adrenals.
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Protein binding of progesterone in plasma
Progesterone is transported in blood bound to certain
plasma proteins. The known proteins are cortico steroid
binding globulin (CB3), albumin and®0-- acid glycoprotein.
The affinity of this binding is dictated by the affinity
constant (k-value) of the binding reaction. CBG binds
progesterone with high affinity, of the order of 10^ 8
but its concentration in plasma is only about 3.8 mg/l. The
affinities of albumin oro(l - acid glycoprotein, to which
progesterone also binds, are of a lower order (104~5 5Ut
their plasma concentrations are higher (750 mg/l for^f 1- acid
glycoprotein, and 50 times more for albumin). Yannone, et al.,
(1969), have calculated the total amount of protein bound
progesterone to be 91% in pregnant and 92% in women in the
normal menstrual cycles. The albumin-bound and possibly also
the/ 1- acid glycoprotein-bound fraction, in pregnant and the
non-pregnant subject are calculated as 50% and 70% respectively,
while the CBG-bound fraction in the same categories were
calculated as 40% and 22% respectively (Rosenthal, et al„, 1969).
ln vitro experiments protein-bound progesterone has been
shown to be inactive in exhibiting its specific hormonal
activity (Westphal and Forbes, 1963; Hoffman, et al., 1969),
which suggests that protein binding of progesterone in vivo
may be a mechanism by which progesterone makes itself less
available to the target tissues. The binding of progesterone
7
to the proteins is by non-covalent and reversible bonds so
that protein-bound progesterone can be made available by
dissociation to those tissues whose affinities for progesterone
exceed those of the binding proteins. It has been shown that
albumin and/ori(1 glycoprotein-bound progesterone is more
readily extracted (irreversibly metabolized) by the liver than
the portion bound to CBG which is protected from such metabolism
(Rosenthal, et al., 1969). Binding of progesterone to proteins
of high affinity with low capacity, and to proteins of low
affinity with high capacity can therefore have major effects on
its metabolism and hormonal activity.
The presence of a specific progesterone-binding plasma
protein in the pregnant guin£$pig has been reported (Diamond
(££ oJ. ., 1969; Milgrom, et al., 1970). Binding of
progesterone in these animals is raised 100-fold as compared to
non-pregnant animals, whereas cortisOl-binding is raised only
by a factor of 4.
Clearance and metabolism in man
The plasma half-life of progesterone has been determined
by various procedures: (a) following expulsion of the placenta
it was found to have a half-life of 5 min. (Short and Eton, 1959),
(b) following injections and infusions of labelled and unlabelled
progesterone in two non-pregnant subjects the half-life was
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calculated as 25 and 29 min. (Thijssen and Zander, 1966;
Little et al., 1966). (c) following the simultaneous removal
of the foeto-placental unit and corpus luteum in the first
trimester of pregnancy the disappearance of progesterone was
observed to take place in two phases. The half-life from the
disappearance in the first phase was calculated as 6 min. and
from the second phase disappearance as 43 min. (Fylling, 197%*) .
The two-phase disappearance has been explained as follows:
progesterone is rapidly cleared upon entering the vascular
compartment. Clearance is then slowed as it comes in contact
and equilibrates with the tissues (outer pool) from where it
then slowly returns to the blood.
Thus the available evidence indicates that progesterone is
cleared rapidly from the blood. It is not stored in the corpus
luteum as the turnover time, that is, the time taken for the
corpus luteum to release its content of progesterone into the
blood, is only 10 min • - (Short et al., 1963). The amount of
progesterone in the term placentas has been calculated to be
750pg (Zander and von Mdnstermann, 1956). Since this amount
of progesterone is equivalent to the placental secretion for
5 min. (250 mg/day), this finding^suggests that progesterone
is not stored in the placenta (Van der Molen and Aakvaag, 1967).
Studies on the metabolic clearance rates of progesterone
have shown that about half the progesterone given by I.V.infusion
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is metabolized by organs other than liver (Little et al., 1966).
Changes in the equilibrium and the extent to which ratios of
free progesterone to that which is bound to the different plasma
proteins change when blood passes through the various receptor
organs are not fully understood. The metabolic clearance rate
of progesterone is the same in males, ovariectomised women and
pregnancy, but is about 25% greater in menstruating women in
whom however, no difference in metabolic clearance rates is
observed between follicular and luteal phase (Lin et al., 1972).
Progesterone is usually metabolized by reduction,
hydroxylation and conjugation, but the products vary in specific
tissues. The liver metabolizes progesterone mainly to ring
A-5 j5-pregnane derivitives and hydroxylation products (Dorfman
and Ungar, 1965). The target tissues (endometrium and
myometrium) metabolize progesterone mainly to ring A-5«< - pregnane
derivitives and hydroxylation products (Bryson and Sweat. 1967,
1969).
Physiologic and Biological role
The main physiological effects of progesterone have been
described (O'Malley, 1969) as follows:
(a) Preparation of uterine endometrial cells so that favourable
conditions are present for the receipt and implantation of
the embryo.
(b) Exertion of a "blocking effect" to reduce the excitation
of uterine muscles resulting in stoppage of their rhythmic
10
contraction - excitation activity (Csapo, 1961). This
aids in the retention of the embryo in the uterus,
(c) Stimulation of the alveolar development of breast tissue
and so preparing it for lactation.
The present evidence suggests that metabolites of
progesterone, e.g. 5«<.-pregnane 3,20 dione and 20 -
I-
hydroxypregnj^3-one are less active than progesterone itself.
4
Experiments in rats showed greater enzyme activity of A "5 -
reductase, 3&- hydroxysteroid dehydrogenase and 20®<- hydroxy-
steroid dehydrogenase in the oestrogen dominated phase (oestrus)
reflecting greater progesterone metabolism than in pseudopregnancy
or pregnancy (Wiest, 1969). The concentrations of progesterone
in rat myometrium were higher than in peripheral plasma in early
~h- e?je
pregnancy, while no differences in the levels of 20°(~hydroxypregnjy
3—one were observed between the ttvo) This suggests a longer
half-life of progesterone in the myometrium (Wiest, 1969).
-If—erie.
20"(~ Hydroxypregnj^3 -one is ineffective in supporting decidual
reaction, during implantation and in maintaining or prolonging
the pregnancy (Wiest, 1969). 5<st-pregnane 3,20-dione when
administered exogenously in rats showed weaker biological activity
than progesterone (Armstrong, 1970). From the available evidence
it therefore appears that the biological activity of progesterone
resides in the molecule itself (Wiest, 1969).
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Role in Male Physiology:
The available evidence does not support the view
that there is a physiological role for progesterone
production from the testis. In males, circulating progesterone
is mainly adrenal in origin. Blood production rates in
males and ovariectomised women are not significantly different
(Little et al 1966).
Biosynthetic evidence leads to a similar conclusion.
Progesterone is not found concentrated in testicular tissue.
It is also shown to inhibit the rate of formation of
androgen because of its inhibitory activity on the enzyme
system - the C-17-20-lyase responsible for side chain
cleavage (Huseby et al 1961). In vitro evidence in testis
A 4
suggests that the /\ pathway which includes progesterone
as an intermediate is of minor importance in the synthesis
aTict T-ros.71
of androgens (Yanihara 1972).
Failure of plasma progesterone levels to change in
response to HCG stimulation or fluximestarone supression
(Strott et al., 1969J) provides further evidence against any
significant contribution of the testis to circulating
progesterone levels.
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Role in Adrenal Physiology:
Hechter and Pincus (1954) first suggested that
progesterone was the key intermediate in the synthesis of
Cortisol from their invitro studies on the adrenal tissue.
This notion was however disproved by the invitro studies of
Weliky and Engel (1963) on hyperplastic human adrenal
cortical tissue when they showed that radioactive pregnenolone
was converted to Cortisol independantly through 17-hydroxy
pregnenolone, 17-hydroxy progesterone and deoxy-cortisol
while no conversion to progesterone was observed. Deshpande
et al. (1970) injected radioactive pregnenolone, 17-hydroxy
pregnenolone and progesterone into the adrenal artery of
patients with advanced breast cancer and from the isolation
of steroids in the adrenal vein demonstrated that Cortisol
was mainly synthesized from A 5 steroids rather than from
progesterone. This was confirmed using larger amounts, of
endogenous ^ -steroids in tissue pools. Infusions of
ACTH over a 3 h period in normal men were found to
produce a 4-6-fold response in the concentration of
steroids accompanied by only a 2-fold response in the
concentration of progesterone and 17-hydroxy progesterone
(Bermudez and Lipsett 1972). This suggests progesterone
involvement only in a minor way in the synthesis of
Cortisol, at least under conditions of stimulation or stress.
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A continuous basal secretion of progesterone by the
adrenal gland has yet to be demonstrated. Progesterone has
been identified in adrenal venous effluent of postmenopausal
women after stimulation with ACTH (Short I960). That plasma
progesterone rises in response to ACTH and not to HCG
stimulation (Strott et al. , 1969j) strongly suggests that
the incre'ruent is secreted by the adrenal glands although
this does not prove its basal secretion by the adrenal
gland.
Role in Female Reproduction:
When the concentration of a hormone in the venous
blood of an endocrine organ is greater than that in the
arterial blood supplying that organ or in the peripheral
blood, the hormone is considered a secretory product of
that endocrine organ (Eikness and Hall 1965). By this
definition progesterone clearly qualifies as a secretory
product of the ovary (Mikhail 1970, Lloyd et al., 1971).
Of the main steroid-producing functional units of
the ovary, the follicle, corpus luteum and the stromal or
interstitial tissue; the stromal tissue is the least
significant source of ovarian progesterone. This has been
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shown in invitro experiments with stromal tissues from
normal human ovarian sources (Rice ^ 1966) and also in
in vivo systems when the concentration of progesterone in
the ovarian vein on the side of the contralateral ovary was
shown to be significantly lower than that from the ovary
containing the ripening follicle (Mikhail 1970, Lloyd
et al., 1971).
Graafian Follicle:
Two cell types constitute the human Graafian
follicle - the granulosa and theca interna cells. The
former envelopes the oocyte and developes several layers with
the growth of the follicle. The granulosa cells are devoid
of blood vessels whereas the theca interna cells (the
outer layer being theca externa) are well supplied with a
plexus of blood capillaries and lymphatics. Biosynthetically,
in in vitro experiments, theca interna cells have been
shown to utilise the 5- pathway more efficiently than
the granulosa cells which again in in vitro studies have
been shown to synthesize progesterone as the major product
(Ryan and Petro 1966). The synthetic capacity of granulosa
cells to secrete progesterone at different stages during
the follicular phase was also shown by the in vitro tissue
culture experiments using these cells (Channing 1970).
Although this in vitro biochemical evidence demonstrates
15
the synthetic competence of granulosa cells to synthesize
progesterone, the amount secreted by the follicle in vivo
is small as judged by the peripheral plasma progesterone
concentrations in the follicular phase of the cycle.
A significant portion of the follicular-phase progesterone
is considered to be adrenal in origin. Progesterone levels
in the follicular-phase of normally menstruating women
increased four-fold in response to ACTH stimulation
*
(Strott et al., 19691). However, significant amounts of
progesterone were measured in the follicular phase of a
bilaterally adrenalectomized xvoman (Abraham et al., 1973a)
maintained on replacement therapy with fluorinef (0.05 mg/day)
and Cortisol acetate (40 mg/day).
These findings together pose the question as to why
the granulosa cells which synthesize appreciable amounts
of progesterone in vitro actually secrete only very small
amounts in vivo. One explanation was based on an observation
that removal of the oocyte from mature follicles of
oestrus rabbits stimulated progesterone secretion by the
granulosa cells (El fouli et al., 1970). This suggested
the presence of a luteinizing inhibiting factor associated
fwith the presence of the oocyte (Armstrong 1970A. The
progesterone secretion by the granulosa cells of mature
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follicles in culture medium (Channing 1970) where they were
removed from proximity to the oocyte was cited as additional
evidence for the presence of the luteinizing inhibiting
factoro As the luteinization of granulosa cells in culture
medium does not involve a surge of LH and FSH it was
suggested that the function of such a surge in a normal
cycle was to suppress the ovum-induced signal to luteinization
(Schwartz and McCormack 1972). However there is no direct
evidence for the presence of a luteinizing-inhibiting
factor and whether replacing the oocyte in the follicle
would inhibit the secretion of progesterone is not known
(Baird 1973).
An alternative explanation for the low progesterone
levels in the follicular phase is based on the lack of
adequate oxygen and food supply required for full
steroidogenesis by the granulosa, cells. The granulosa
cells are devoid of blood vessels and the synthesized
progesterone may not reach the vascular system other than by
diffusion. For the same reason the required nutrients
and precusers for steroid synthesis may reach these cells
in sub-optimal amounts (Short 1964). It. has recently been
shown that the partial pressure of oxygen in the follicle
is low until the midcycle LH surge when secretion of
progesterone commences (Fraser et al., 1973). Present
evidence therefore suggests that the partial pressure of
oxygen in the follicle is altered under the influence of
the midcycle LH surge and that this is associated with the
stimulation of steroidogenesis including progesterone
synthesis.
Role for Progesterone during Kid-Cycle:
Under experimental conditions both progesterone surd
oestradiol have been found capable of inducing a surge
-thit of
of LH and/or FSH of the magnitude similar to J^the midcycle
peak of gonadotropins. However there is overwhelming
evidence in favour of oestradiol rather than progesterone
as the natural trigger of the midcycle gonadotropin surge
in the menstrual cycle.
In earlier studies on normally menstruating women a
urinary oestrogen peak; was shown to occur coinciding with
or preceding the midcycle peak of gonadotropins by 2 or one
days whereas the rise in urina^ry pregnanediol levels occurred
<3?id rRtthev/
only 1-4 days after the oestrogen, peak (Brownf\1962,
Burger et al 1968, Goebelsmann et al„,1969). Later studies
on the normal menstrual cycle, in which plasma oestradiol
and LH levels were measured simultaneously by sensitive
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techniques, also showed a rise and fall of oestradiol
before the LH peak (Corker .et al. , 1969). The ability
of oestradiol to induce an LH peak has been shown by
giving multiple subcutaneous injections Or single
intramuscular injection of oestradiol benzoate to rhesus
monkeys in which elevated levels of plasma oestradiol
sustained for more than 12 h induced the LH peak
resembling the midcycle peak after 24 - 48 h (Knobil
et al., 1972). Administration of exogenous oestrogens
for 1-3 days during the mid-follicular phase (days 7-9)
resulted in a surge of gonadotropins, after 12 - 24 h ,
similar to those occurring spontaneously in the midcycle.
Varkteviele et al. (1970) observed that in some infertile
women who were being treated with gonadotropins, ovulation
occurred in the FSH phase of the treatment even before the
administration of HCG which was given to induce ovulation.
This ovulation was preceded by an increase in urinary
oestrogens without a concomitant rise in pregnanediol levels.
Johansson and Wide (1969) in a detailed study on the
relationship between the midcycle LH release and changes
in plasma progesterone levels showed that the first
detectable rise in progesterone concentration occurred on
the day of the LH peak and therefore some 24 h after
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the first detectable increase in plasma LH. Similar
observations have been made by Vandewiele et al. (1970).
All the evidence therefore implicates oestradiol as the
primary trigger for the midcycle surge of gonadotropins
rather than progesterone which shows no change in its
concentration of a kind which could act as a signal for
the release of LH.
However, progesterone has also been shown to induce LH
release under certain circumstances. In a group of castrate
and postmenopausal women in whom endogenous gonadotropin
levels were suppressed by diethyl stilboestrol (15 mg/day)
or ethynyl oestradiol (0.2 - 0.5 mg/day), progesterone
(10 mg intra muscular) or medroxy progesterone (10 - 20 mg I.M.)
was then given. This treatment induced an LH and FSH
surge closely resenibling the midcycle gonadotropin peak.
Further, a second gonadotropin surge was not obtained on
continuation of the progestogen treatment. These observations
lead the authors to suggest progesterone as the natural
trigger for the midcycle surge of gonadotropins although
they did not measure the circulating progesterone levels in
their studies (Odell and Swerdloff 1968). Progesterone-
induced LH/FSH surges xvere also observed by N<iliius&nd
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Wide (1971). Their studies were carried out on 20
postmenopausal women given 10izg of ethynyl oestradiol
daily for four weeks before starting the progesterone
treatment (10 mg or 100 mg I„M. in oil). By measuring
the plasma progesterone levels achieved with this
regimen they showed higher doses to be less effective than
the 10 mg dose. They also showed that xvhen progesterone
treatment was given in the absence of pretreatment with
oestrogens, no major changes in the serum concentrations of
gonadotropins xvere observed. However, the magnitude of the
LH surges they obtained in. most subjects were not particularly
impressive and it is arguable that these surges were the
result of a positive feedback response to progesterone
administration or were in fact the natural episodic pattern
of LH release of high amplitude and slow pulse rate observed
in the luteal phase in women (Sante.n and Bardin 1973) and
during progesterone administration in rhesus monkey
(Knobil et al. 1972). The studies of Leydendecker et al.
(1972) were carried out on a group of women that included
castrate eugonadal, postmenopausal women and those with
primary amenorrhoea who were all receiving 60 jug of ethynyl
oestradiol per day before the experiments. These workers showed
that intramuscular injections of varying doses, 2-0,50,200 mg
of microcrystalline progesterone were able to induce an LH
^1
surge within 3 - 16 h . Following an intramuscular
injection of 20 mg of microcrystalline progesterone the
circulating levels in plasma rose, within 90 - 120 min ,
to 1-2 ng/ml, a concentration that is similar to that found
on the day of the LH peak in the normal cycles. The
injections at higher doses (50 or 200 mg) of progesterone
produced circulating concentrations similar to the luteal
phase levels. These experiments suggest that a progesterone-
induced positive feedback effect is achieved once a certain
threshold concentration of progesterone in plasma is reached.
These experiments and the previous observations have led to
the present concept of the role of progesterone in the positive
feedback mechanism which gives rise to the midcycle LH surge.
This is as follows: although progesterone does not trigger
the midcycle gonadotropin peak (as its first detectable
increase in concentration is seen only after the start of
the LH surge), it may potentiate the oestradiol-initiated
LH surge and so increase its magnitude (Leydendecker et al.,
1972).
On the other hand progesterone, when present at
certain inhibitory threshold, levels, has also been shown to
suppress the LH surge and thus inhibit ovulation. When
progesterone was injected in a group of rhesus monkeys in
doses of 0.5, 2 and 5 mg from the beginning of the menstrual
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cycle, blocked equally at all dose levels both the rise of
LH and ovulation as observed at laparatomy and by comparison
with control animals (Spies and Niswender 1971). Failure of
oestradiol to induce an LH surge in the presence of
progesterone is shown by the experiments in the rhesus
monkey (Knobil et al., 1972). Administration of oestradiol
benzoate during the luteal phase of these animals failed to
produce an LH surge when the progesterone concentrations
were high (4 ng/ml). When the newly formed corpus luteum
was removed and the concentrations of plasma progesterone
had decreased to undetectable levels the oestradiol benzoate
administered on the same day of the menstrual cycle produced
a sharp LH peak. In the studies of Swerdloff and Odell
(1969) on eugonadal women with normal cycles, there xvere
multiple LH peaks in the oestrogenic phase during a regimen
of oral sequential contraceptive pill (mesterenol, 80y^g
for 15 days ) but when a progestogen was administered
(chlormadinone acetate 2 mg) only one sharp peak occurred.
The inhibitory action of progesterone may be brought about
nervous 5Xfteni
by blocking the I as suggested by the experiments
of Zeilmaker and Mo.ll (1967). They were able to induce
ovulation in 5 day cycling rats by electrochemical
stimulation of the median eminence or the pre-optic area.
However when 10 mg of progesterone was given on day-3
of the cycle ovulation was blocked and could be induced by
the stimulation of median eminence. The role for the
inhibitory effect of progesterone then lies in preventing a
second surge of LH from being initiated by the luteal rise
in oestradiol or progesterone itself (Leydendecker et al.
1972).
The positive feedback effect of progesterone thus
offers a fail/safe mechanism whereby the oestradiol-
initiated full surge of LH is ensured. The inhibitory effect
of progesterone, by preventing further LH surges during the
luteal phase allows only one ovulation to take place in the
menstrual cycle.
Role in Ovulation;
The mechanism of follicular rupture which is followed
by extrusion of the ovum is now generally considered to
involve an increase in tension of the follicular wall.
Studies in the past have shown the involvement of
progesterone in the process of ovulation. Some of these are
based on its ability in vitro to increase the di.stensibi.lity
of the follicular wall. Progesterone, but not oestrogen,
LH or cyclic AMP, was able to increase the distensibility
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of the follicular wall as observed in culture experiments
using follicular strips from the sow. Further, when this
distensibility was blocked by the simultaneous addition of
cyanoketone, an inhibitor of 3f3 - hydroxysteroid dehydrogenase
involved in the conversion of pregnenolone to progesterone,
only progesterone could reverse the blockade (Rbndebl 1970).
Of the various steroid enzyme inhibitors used to block ovulation
induced by LH in pregnant mare serum (FMS) treated rats,
cyanoketone was the most effective (Lipner and Greep 1971).
Based on similar experiments the role of progesterone
in the process of ovulation was explained as follows; The
initiation of ovulatory process started with the midcycle LH
surge finally resulting in the increased steroidogenesis.
Thenain product, progesterone, then caused the stimulation of
the collagenqse-like enzyme destroying the collagen-like
framework in the follicular wall. These developments caused
the increase in distensibility of the follicular wall and
finally its rupture (Rtmde&l 1970, Schwartz and McCormack
1972).
More recent evidence, however, does not support a
role for progesterone in the physical process of ovulation
i.e. follicular rupture. In the rat there is a preovulatory
retention of uterine fluid which reflects the inadequate
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concentrations of progesterone necessary for cervical
relaxation and hence uterine fluid release (Armstrong 1968).
Ovulation in rats was blocked by giving the prostaglandin
synthesis blocking agent, indomethacin. This blockade was
not reversed by gonadotropin releasing factor although there
was a loss of uterine fluid suggesting that LH was released
by the pituitary and that this stimulated the production
of progesterone necessary for cervical relaxation. Thus
indomethacin does not appear to block ovulation by inhibiting
ovarian steroidogenesis. Rather, it may block ovulation
by preventing rupture of the follicle and release of the
ovum (Behrman et al., 1972). Release of progesterone in the
absence of ovulation (which again was blocked by indomethacin)
was also observed in rats by Armstrong and Griinwidh (1972).
O'Grady et al. (1972) also were able to block LH-induced
ovulation in rabbits by indomethacin although progesterone
secretion was normal.
The Luteal-Phase:
The synthesis of progesterone by the corpus luteum
is ascribed to the luteinised granulosa cells which together
with the theca interna cells constitute the two cellular
compartments of the corpus luteum. There is no evidence on
the individual steroid secretion patterns of the two cell
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types. In vitro studies in luteal slices have shown the
presence of enzymes of both the /\^ and A5 pathways and also
that it is the j_pathway that is more active (Ryan 1963).
That the A5 pathway in the luteal, phase is not more active
is also suggested by the levels of A5 -steroids (Pregnenolone,
17-hydroxy pregnenolone and Dehydroepiandrosterone), which
as measured by radio immunoassay were not significantly different
fin the follicular and luteal phases (Abraham et al„ 1973f).
Progesterone levels rise in response to the midcycle
LH surge and reach peak levels about a week thereafter.
Although the production rate of progesterone in the luteal-
phase has been calculated to be 15 - 50 mg/day (r,in et
al. , 1972) a dose of 5 mg/day ivas found sufficient to prevent
bleeding following excision of the corpus luteum (Corner
1937). In another study an intramuscular injection of
12.5 mg/day was found adequate to maintain a secretory
endometrium in the absence of endogenous progesterone
production (Jones 1968). An intramuscular dose of 25 mg/day
of progesterone was found to be the ideal dose in maintaining
luteal phase plasma levels as measured by the competitive
protein binding method (Nillius and Johansson 1971).
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It has now been fairly well established that the corpus
luteum does not function autonomously but that it requires
low but continuous secretion of LH to maintain the normal
luteal phase progesterone levels (Vandewiele et al., 1970).
This is supported by experiments where administration of
antisera to HCG (which cross reacted with LH) to rhesus
monkey in their luteal phase resulted in reduced progesterone
secretion and caused premature menstruation (Moudgal et al.,
1972). Although it has a vital role in maintaining the
corpus luteum in humans, LH seems unable to prolong the
life span of the corpus luteum beyond a limited period. Even
high daily doses (1600 I.U. ) of LH given to hypophysectomised
women were unable to maintain progesterone production beyond
22 days (Jewelewicz et al., 1973). The normal life-span of
the corpus luteum in some animal species has been shown to be
controlled by uterine luteolytic factors possibly prostaglandin
F2°<C ( Hil-lardi 197 3). But this does not appear to be the
mechanism controlling corpus luteum regression in humans
as hysterectomy has been shown not to affect normal luteal,
function (Beling et al., 1970). Also, luteal function was
normal in women with congenital absence of uterus as
judged by the timing and magnitude of urinary pregnanediol
and oestrogen levels following the midcycle LH surge
(Fraser et al., 1973 Jj).
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Attempts have been made to study the control of corpus
luteum function by suppressing or blocking progesterone
synthesis in the luteal-phase. One approach was by inhibiting
the synthesis of progesterone directly by enzyme inhibitors.
Cyanoketones and other androstane derivatives which block
progesterone synthesis at the 3 p-hydroxy steroid
dehydrogenase step also block adrenal synthesis of
progesterone (Henzl and Segre 1970). Amino-gluthetirnide
(Salhanick et al., 1972) affects progesterone synthesis in
both the ovary and the adrenals by blocking cytochrome
P-450 activity which is necessary for the conversion of
cholesterol to pregnenolone. A selective inhibition of
ovarian synthesis of progesterone which does not interfere
with its synthesis in the adrenal has not yet been
accomplished (Jewelewicz et al.} 1973). Prostaglandins
infused during the luteal phase in doses sufficient to
cause abortion in mid-trimester pregnancy failed, to affect
the normal luteal-phase (Jewelewicz et al,, 1972).
In another approach for controlling corpus luteum
function progesterone synthesis in the luteal phase has
been shown to be suppressed in varying degrees by administering
oestrogens (Gore et al., 1973), progestagens (Johansson 1971)
and oxymethalone (Klaiber et al., 1973). Their actions are
reversed by the exogenous administration of HCG suggesting
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that these compounds suppress progesterone synthesis
by the inhibition of LH secretion. However, oxymethalone
also blocks 3 p-hydroxy steroid dehydrogenase and isomerase




The fertilized ovum remains in the fallopian tube for
48 h before journeying to the uterus for implantation which
is believed to begin on day 4-6 after entry into the uterus
(Blandau 1961); the implantation being completed on day 12
(Henzl and Segre 1970). In response to implantation
progesterone levels show a sharp increase above luteal
phase levels from around day-8 onwards, at a time when
they show a decreasing trend in a normal luteal phase
(Johansson 1969; Knobil 1973). This increase in plasma
progesterone concentration is believed to be due to
luteotrophic stimulation by HCG. This is supported by the
following evidence. Administration of HCG during the early
or the mid-luteal phase was shown to increase the progesterone
production 2-4 fold:. (Strott et al., 1969^>). No qualitative
differences in the stimulatory action of human LH or HCG
upon progesterone production by corpus luteum were observed
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when either of the two hormones were administered during
the luteal-phase of women with normal menstrual cycles.
Both LH and HCG increased the progesterone production
2-3 fold*.* that of the control cycles and lengthened the
life-span of luteal-phase for up to 8-9 days (Hanson et
al., 1971). Ovulation has been induced by exogenous administration
of HCG after pre treatment with HMG (to promote follicular
development) in hypophysectomised (Gemzell 1965) and
anovulatory women (Yoshimi et al., 1969); (ovulation so
induced in these women also resulted in successful
pregnancies).
However there are two principal objections (Short
1969) to HCG as the luteotrophic stimulus. One is the
absence of HCG at the time of implantation on day 4-6
at a time when there is a significant increase in the
synthesis of progesterone, HCG appearing in blood only
on day-9 after the midcycle gonadotropin surge (Kosasa
1973). The other objection is the inverse
relationship in the circulating concentrations of HCG
and progesterone. The levels of HCG continue to rise
after implantation and reach a maximum between 5-9th
week of gestation whereas progesterone concentration,
although above luteal-phase levels, show a downward trend
during this period. (Yoshimi et al., 1969, Johansson dUd VJl^
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1969). This inverse relationship has been explained
on the basis of refractoriness of the corpus luteum to the
continuous and rising stimulus of HCG.
Generally the corpus luteum is essential for the
foetus up to about 8-9 weeks of gestation. Removal of the
corpus luteum before this period was shown to result in
low progesterone levels and abortion. Removal after day
61 resulted in a slight transient decrease of progesterone
levels followed by a significant rise without affecting the
pregnancy, the rise pointing towards a shift of the site
of progesterone production from the corpus luteum to the
placenta (Csapo et al„, 1972; Holmdahl et al., 1971).
A similar shift of progesterone production to the placenta
at about this time (days 50-60) is also evidenced by the
divergent patterns of circulating levels of progesterone
and 17-hydroxy progesterone. As the placenta lacks the
enzyme 17e< -hydroxylase the . 17-hydroxy progesterone
declining
levels indicate the^ovarian contribution and the rising progesterone
inzreA.sing
levels the^placental contribution (Yoshimi et al., 1S69).
The essential contribution of the corpus luteum to circulating
progesterone levels that are required for maintaining the
pregnancy may in fact be even shorter than 50-60 days, as
oophorectomy 35 days after ovulation has been shown not
to interrupt pregnancy (Tulsky and Koff 1957 }„ The main
role of the corpus luteum in pregnancy thus appears to be
to support the implantation of the conceptus and its
growth for a period thereafter, at the end of which it
becomes dispensible. However, it continues to exist and
function throughout the pregnancy, retaining all the
necessary enzymes for steroid synthesis (Le Ma"ii"e et al.,
1968) and is capable of secretion as judged by differences
in the progesterone concentrations in ovarian vein and
peripheral plasma at different stages of gestation up to
the 40th week (Mikhail and Allen 1967)„
HvftUJl
Plasma Progesterone Concentrations in^Pregnancy:
The progesterone concentrations rise from implantation
to the 5th week of gestation and then show a decreasing
trend from 5th~9th week, the concentrations decreasing from
25 ng/ml to 17 ng/ml in the 9th week (Johansson 1969).
From the 9th week of gestation progesterone concentrations
then rise up to the 37th week from 20 ng/ml to 150 ng/ml
(Tulchinsky et al., 1972) and reflect mainly placental
synthesis of progesterone. At about the 37th week the
concentrations plateau for the remainder of the gestation
period.
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Although progesterone concentrations in plasma
continue to rise in pregnancy its concentration in the
myometrium is reported to be fairly constant suggesting
that the binding capacity of the myometrium is limited
(Runnebaum and Zander 1971). This also suggests that the
target tissues may not require all the progesterone that
is synthesized during gestation.
Placental synthesis:
The human placenta synthesizes more progesterone than
that of any other known species, 250 mg of the hormone being
secreted per day (Van der Molen and AakVaag 1967). It
possesses efficient side-chain cleavage, 3 {3 -hydroxy
steroid dehydrogenase and isouterase. enzyme systems (Mason
and Boyd 1972). Although the placenta can synthesize
progesterone de novo from acetate (Van Leusden and Villee
1965), from pregnenolone and from its sulphate conjugate
(Pion et al., 1966), these routes are quantitatively less
important than the synthesis of progesterone from maternal
cholesterol (Hellig et al. 1969). Placental progesterone does
not depend on a contribution from the foetus because the
progesterone concentrations in the umbilical vein far exceed
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those from the umbilical artery and also that of the
uterine artery (Harbert et al., 1964). Plasma progesterone
levels (Lurie et al., 1966, Wiest 1967) or urinary
pregnanediol levels (Cassr-.m£r 1959) in pregnancy, therefore,
did not show significant alterations in the event of foetal
deatho Growth of the placenta is accompanied by a
proportional increase in DNA (i.e. there is an increase in
cell number of placenta). At about 35-36 weeks an increase
in DNA ceases and this is accompanied by a slowing in
placental growth rate. As the peripheral blood concentrations
of progesterone plateau at about this period they may also
closely reflect placental growth (Davies and Ryan .1972).
Role for Progesterone in Pregnancy:
Although progesterone, in association with oestrogens,
promotes the growth of the uterus, its principle function
in pregnancy is generally suggested to be to exert a
"blocking effect" to reduce the excitation of uterine muscles
resulting in inhibition of their rhythmic contraction-
excitation activity (Csapo 1961, Davies and Ryan 1972,
Heap et al., 1973). If the secretion of progesterone is
drastically reduced or abolished by ovariectomy or by
placental dislocation in pregnant rabbits (day 25 post
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coitus) the contractile activity of the myometrium increases
within 43 hours. If progesterone is injected the activity
is abolished for 48 hours (Kumar 1967). Myometrial
contractions of the human uterus can be inhibited by
progesterone treatment in non-pregnant but not in the late
pregnant or parturient subjects (Csapo 1969).
If the myometrial activity is inhibited in pregnancy
by progesterone then at parturition, this activity should
be associated with the removal of the inhibition by
progesterone presumably because enough hormone is not
available due to insufficient concentrations. However,
high progesterone levels were measured in the uterine
vein and peripheral plasma at a time of induced abortion
after the intra amniotic administration of hypertonic
saline (Short et al 1965) and in the peripheral plasma at
labour (Yannone et al., 1969). It has nevertheless been
shown that the myometrial cells in the vicinity of the
placenta are less contractile than in the interplacental
areas, and it is suggested that the growing volume of the
uterus and its distance from the placenta i.e. "the volume
to the progesterone ratio" may be a crucial factor in
determining the progesterone block and the normal, gestation
period (Csapo 1969). Other factors such as plasma
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protein-binding, metabolism, cytoplasmic "receptor" proteins
may also be involved (Heap et al 1973) suggesting that
regulation of myometrial activity at the cellular level may







Initial attempts to carry out progesterone measurements
were based on biological activity and were made by Clauberg
et al. in 1933„ They failed to detect progesterone activity
in extracts from samples of between 235 and 335 ml of blood
taken during various phases of the menstrual cycle (or
during pregnancy). Attempts to detect progestational
activity similarly failed even when 500 ml of human pregnancy
blood or 70 ml of rabbit pregnancy blood were employed;
these efforts were finally rewarded only when 8-12 litres
of human pregnancy blood were used when a progestational
activity equivalent to 1 rabbit unit of activity was
measured.
The first successful attempt to measure progesterone in
peripheral blood was made in 1954 when the isolation and
chemical identification of the hormone from the blood of
pregnant women was reported (Zander 1954). This determination
was based on ultraviolet absorption at 240 nm , resulting
A 4
from the presence of the ^ 3 oxo structure in the
progesterone molecule. A sensitivity of 500 ng in 1 ml
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plasma was obtained. in later developments of this method
the sensitivity of the spectrophotometric detection was
increased by the formation of progesterone derivatives with
2-3 fold increased molar absorbances resulting in
sensitivities down to 40 ng (Watson et al. 1967).
Solutions of progesterone or its derivatives can
be made to fluoresce by reaction with a strong acid or
base. Based on this property, fluorimetric methods for
determining the progesterone concentration in plasma have
been developed (Short and Levit 1962, Heap 1964). Although
fluorimetric methods are potentially more sensitive than
spectrophotometric methods they also give high non-specific
blank values which lower the sensitivity of the method.
The lower limit of detection for accurate measurement is of
the order of 10 ng (de Jong and Van der Molen 1970).
Because of their low sensitivities the spectrophotometric
and fluorimetric methods are not suitable for measuring
progesterone levels in non-pregnant individuals, for
example, they are not able to distinguish between the
progesterone levels in the follicular and luteal-phases of
the menstrual cycle (Van der Molen and Aakvaag 1967).
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Marked improvements in sensitivities occurred with
the development of double isotope derivative (DID) and
gas liquid chromatography (GLC) methods and with their
emergence, progesterone could be reliably measured in the
plasma of non-pregnant subjects. In the GLC system the
stationary phase is a liquid film held on an inert solid
support, and the mobile phase is a gas flowing continuously
over the surface of the stationary phase. The concentration
of the sample being assayed depends on its vapour pressure
at the operating temperature which in turn is related to the
boiling point and hence its molecular weight. Thus in the
GLC system a volatile derivative of progesterone has to be
formed and suitably purified. The vapours of this derivative
in the mobile gas phase are blown over the stationary
phase and these vapours travel at a rate which is proportional
to the partition coefficient of each component in the
sample between the two phases.
The DID technique, in which use is made of two
radioactive tracers differing in their energy spectra,
incorporates the technique of isotope derivati-ve and isotope
F14. T .
dilution. For example, a known amount of L Cj*Tabelled
progesterone is added to the plasma to correct for the
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recovery losses. The plasma is extracted and the progesterone
is purified. The purified extract is then reacted with a
3 3
[ H]—labelled reagent. The [ H]-labelled progesterone
derivative so formed is further purified. The amount of
3
[ h] radioactivity in the final residue is proportional to
the amount of progesterone or its derivative. The accuracy
and precision of the estimation is dependent on the ratio
14
of the mass of [ c] progesterone added (to correct for-
recovery) to the mass of progesterone present in the
sample.
The detection limits for progesterone of the various
GLC and DID methods as published vary from 1 - 10 ng (Van
der Molen and Aakvaag 1967). Although these methods may
be used for assessing luteal function, the amount of plasma
they require and the number of extraction and purification
steps involved to ensure the specificity of progesterone
measurement make these two methods unsuitable for routine
estimations of progesterone. However, they remain valuable
as methods for the additional identification of progesterone.
More recently, the principles of competitive protein
binding (CPB) (Murphy 1964) and radio immuno assay - RIA - Yalow
and Berson 1960, Ekins 1960) have been adopted for the measurement
of progesterone in the blood. With the application of these
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techniques it has become practicable to estimate progesterone
in multiple samples on a routine basis for physiological and
clinical investigations. This is largely because of the
vastly improved sensitivities of these techniques which have
obviated the necessity of using the large amounts of plasma
samples required in GLC and DID methods. Progesterone
methods based on CPB and RIA techniques are also very much
less laborious. The general principle of CPB and RIA
techniques can be described as follows.
The hormone to be measured is allowed to compete
with a,trace quantity of radioactive hormone for the
binding sites of a fixed mass of antibody or other
specific protein. The saturation of the binding sites
results in the partition of the hormone between bound
and free fractions which are then physically separated.
The change in the ratio of bound to free hormone3 as shown
by the distribution of radioactivity between the fractions
reflects the total amount of hormone present. If the
distribution of labelled hormone between the bound and
free fraction of a set of standards is similarly determined
then a standard curve can be constructed. The amount of
hormone to be measured can then be quantitatively determined
by comparison xvith the standard curve.
42
The binding protein most used in the CPB methods of
progesterone is the plasma glycoprotein, transcortin
or corticosteroid binding globulin (CBG). Pregnancy plasma
which contains three times the normal concentration of CBG
found in non-pregnant subjects has been used as a source
of the binding protein after the removal of endogenous
steroids. In addition, plasma from oestrogen treated normal
or ovariectomised women; and plasma from normal or oestrogen
treated dogs has been used as a source of CBG (de Jong and
Van der Molen 1970).
The high sensitivities of progesterone-CBG assays
are due to the high energy of the binding reaction of protein
to progesterone. The association constants of human CBG-
progesterone complex at 4°,"» is 7 x 101" i/h- ( 1 ml/450 pg) and
8 o
decreases to 0.9 x 10 1/^ (1 ml/3.5 ng) at 37 (T* (Burton
and Westphal 1972). CBG also binds certain other steroids
with similar affinities and these include Cortisol,
corticosterone, 17 .-hydroxyprogesterone, 11-deoxycorticosterone.
Assays using CBG for the measurement of plasma progesterone
therefore require a prior purification step (de Jong and
Van der Molen 1970). Some such assays use a selective
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solvent extraction of progesterone in^°a non-polar solvent
and the need for chromatographic purification is then obviated
(Johansson 1969, Lurie and Patterson, 1970; Demetrious and
Austin, 1971). The specificity of the progesterone
measurement so achieved is adequate for monitoring luteal
function but not for measuring follicular levels of
progesterone as appreciable quantities of 17-hydroxypro-
gesterone (in particular) are extracted in a non-polar solvent
The other high affxnity protein used in CPB methods
for progesterone is the progesterone binding protein
(PBP) ivhich is synthesized during pregnancy in guinea pigs.
It is a glycoprotein of «< - or globulin mobility, it has
-7
a mol. wt. 100000 and its plasma concentration 5 x 10 M.
o
The association constant of PBP for progesterone at 4 Q' is
4.8 x 109 1/M (1 ml/65 pg) and 3.9 x 108 l/M (1 ml/800 pg)
o
at 37 C (Burton and Westphal 1972). It discriminates
well against Cortisol, corticosterone and 17- hydroxy-
progesterone but shows limited specificity towards 20 a( —
hydroxypregn-4-en-3-one, 5o( -pregnane-3,20-dione,
testosterone, 5«< -dihydrotestosterone and deoxycorti¬
costerone. Therefore for measuring progesterone levels such
as those found in men and in the follicular phase a prior
chromatographic purification is required. By combining the relative
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specificity of PBP with the non-polar solvent extraction of
progesterone, assay methods have been developed that axe
adequate for assessing luteal function without a
chromatographic purification (Swain 1972, Pichon and
Milgrom 1973).
The application of the RIA technique to progesterone
measurement has resulted in improved sensitivities and
specificities due to higher association constants and a
higher specificity of antibody for progesterone. Compared
to CPB methods, development of the RIA method is expensive,
as it takes from weeks to months to raise an antibody of the
required titre, sensitivity and specificity. RIA methods,
however, prove much cheaper over long periods as many
thousands of assays of progesterone can be performed over
months or years with a single sample of antiserum. Because
the binding protein has a lower association constant for
progesterone than does the antibody it is relatively easier
to separate the free and bound fraction using antibodies
although equilibration times are slightly longer (minutes
to hours) than those required in CPB assays (seconds to
minutes). Thus RIA methods are more robust and versatile
than CPB assays.
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The studies of Landsteiner (1945) demonstrated that
antibodies could be elicited to small molecular weight
compounds by attaching them to large immunogenic protein
carriers. The techniques for preparing steroid protein
conjugates were later studied in detail (Goodfriend and
Sehon 1958; Lieberman et al., 1959). Carboxylic acids were
first attached to steroids by forming derivatives through
the existing =0 group (oximes) or -OH group (hemi
succinates, chlorocarbonates) of the steroid nucleus
(Lieberman et al., 1959). Steroids were then coupled
to the protein through covalent bonds between the -COOH
t-dimib ©f lysmt resides
group of the steroid derivative and theJL groups^of the
protein to form the biologically stable - CO-NH linkage.
To prevent the cross linking amongst the -COOH group and
-NH^ group of the protein molecule during the coupling
reaction, the steroid derivatives (containing the
carboxylic group) were first activated to form the
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During the early period of development, steroid-
protein conjugates were made by using the existing functional
groups of the steroid molecule for coupling to the protein.
The antisera so produced exhibited limited specificity,
for example, antisera to testosterone raised by coupling
at the 17-hydroxy position to BSA were only poorly able to
detect structural changes embracing this part of the molecule
whereas changes in the A ring were clearly recognized by
these antisera (Beiser et al„, 1959). These authors con¬
cluded that the portion of the hapten molecule farthest-
removed from the point of attachment to BSA determined to
a great extent the specificity of an antiserum. In
later studies (Midgley and Niswender 1970, Lindner et al.,
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1970) conjugation of steroids to protein was performed at
different positions of the steroid molecule and the
specificities of antisera so produced was found to depend
on the site of conjugation to protein. It was shown that
conjugation to the protein at sites distal to the functional
groups of the steroid molecule resulted in the production
of antisera of higher specificity (Niswender and
Midgley 1970) as all of the biologically active groups
were then represented in the immunogen.
For the progesterone method to be presented in this
thesis the selection of liK -hydroxyprogesterone and
6 p-hydroxyprogesterone as the site for coupling to bovine
serum albumin in the immunogens has been made on the basis
of similar considerations. Hemisuccinates rather than
chlorocarbonate derivatives of progesterone have been
prepared. The longer link which they provided between the
steroid and protein was considered to have afforded the
steroid moiety a better chance of being clearly recognized
in the conjugate. Conjugation of the 6 {3and 11 *<-■
hydroxyprogesterone derivatives to bovine serum albumin
was performed by the mixed anhydride reaction (Erlanger et al.
1957).
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Since the work for this thesis was started in the
beginning of 1971, 10 radio-immuno assay methods for
measuring progesterone in human blood have been reported.
In the first two published methods antisera were raised
by coupling to the 2l-position (Abraham et al., 1971) and
to the 3-position (Furuyama and Nugent 1971) of the
progesterone molecule. These antisera showed limited
specificity for the steroids having structural differences
from progesterone which were near the site of conjugation
e.g. 17 hydroxyprogesterone, Cortisol; and 5<*( -pregnane-
3 ,20-dione and pregnenolone respectively. Consequently,
in these methods a prior chromatographic purification of
the progesterone was essential.
In 1. . - other methods, antisera have been raised
to the lloC. -hydroxyprogesterone bovine serum albumin
conjugate. As noted by Cameron and Scarisbrick (1973)
the specificity of the antisera is not solely a function
of the site of conjugation to the protein and these
antisera which are raised against the 11 -position vary
in their respective specificities to the same steroids.
For example, the specificity of one antiserum to 11
hydroxyprogesterone-BSA conjugate shows significantly
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high cross reactions with 5«C-pregnane-3,20-dione and
17-hydroxyprogesterone (Youssefnejadian et al., 1972)
as compared to other reported antisera. A chromatographic
purification of progesterone to be assayed is therefore
necessitated when using the former antiserum. However,
antisera to lle^ -hydroxyprogesterone-BSA conjugates
(as reported in all other methods) have generally
exhibited a specificity which has allowed accurate
progesterone measurements to be made without a chromatographic
purification for plasma from men, postmenopausal women
and the follicular-phase of the menstrual cycle.
Specific antibodies to progesterone have also been
produced by coupling at the 6 -position (Niswender 1973,
Jones and Mason 1974), 6 p-position (Lindner et al.,
1972, Riley et al., 1972, Niswender 1973, Jones and Mason
1974) and 7^ -position (Bauminger et al., 1973), of the
progesterone molecule. These antisera generally show
appreciable cross-reactions with steroids such as
pregnenolone and 5°^ -pregnane-3, 20-dione although in
other respects their specificity is generally similar to
that of antisera to 11°^ -hydroxyprogesterone-BSA conjugates.
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Nevertheless,
i^4'ssay methods based on antisera raised to progesterone
conjugated at the 6 or 7 positions have not been reported
presumably because they suffer from greater non-specificity
in this regard and do not provide any compensating








The following radioactive steroids were obtained
from the Radio-Chemical Centre, Amersham, Bucks., U.K.:
specific radioactivity
3
l"C-2oC- [(n) - H ] Progesterone 53 Ci/m mol
3
1,2,6,7- [(n) - H] Progesterone 110 £i/m mol
3
7- [(n) H] -17®C -Hydroxyprogesterone 10.2 Ci/m mol
3
1,2- [(n) H] - Cortisol 40 ci/m mol
76<- Rn) 3H] - A5 - Pregnenolone 18 Ci/m mol
Following radioactive steroids were acquired from
colleagues:
3
lc/-2o^ - [(n) H] 20K -Hydroxypregn-4-en-3-one 40 - 60 C" i/m mol
3
7 - [(n) H] Androst-4-ene-
3,17 - dione 6 Ci/m mol
3




Progesterone, 11^ -hydroxyprogesterone, 17-
hydroxyprogesterone, corticosterone and cortisone were
from Koch-Light Laboratories Ltd., Colnbrook, Bucks., U.K.
and androst-4-ene-3,17-dione was from Organon Laboratories
Ltd., Newhouse, Scotland, U.K: Progesterone,
11(3 -hydroxyprogesterone, 11-oxo progesterone, 11-deoxycorti-
costerone, 11-deoxycortisol (compound S), Cortisol,
dehydroepiandrosterone (DHA) and. cholesterol were from
Sigma London Chemical Co. Ltd., Kingston-upon-Thames, U.K.:
6p hydroxyprogesterone, 5»(-pregnane 3,20-dione,
5p -pregnane 3,20-dione were from SteraLoids, 140
Chichester Road, Croydon, U.K.: 20-hydroxypregn-4-
en-3-one, 20 p-hydxoxypregn-4-en-3-one, 30( -hydroxy-5 p-
pregnan-20-one, 5c»( -pregnane 3&C, 2Q&C -diol,
5 o^-pregnane-3 P , 200<.-diol, 5 P -pregnane-3, 20&\ -diol
pregnenolone (3 P-hydroxypregn-5-en-20-one) and
progesterone were from the M.R.C. reference collection,
Department of Chemistry, Westfield College, Hampstead,
London N.W.3.
Biological reagents:
Freund's complete and incomplete adjuvant was
purchased from Difco Laboratories, East Molesey, Surrey.
The non-immune rabbit serum and the donkey anti-rabbit
serum was from Wellcome Research Laboratories, Beckenham
England. Bovine serum albumin (BSA) Cohn fraction IV
was from Armour Pharmaceutical Co. Ltd., Eastbourne, U.K
Reagents;
Sodium salts, Naj_ HF04 and NaH£ F04 (BDH Anala R)
were used to prepare the phosphate buffer. Silica gel
(60 - 120 mesh), gelatin and sodium azide were BDH
laboratory grade and all the other common laboratory
chemicals were AR grade. Succinic anhydride, laboratory
grade, was from Koch-light laboratories. Tri-n-butyl
amine and isobutyl chloroformate (stabilised with
calcium carbonate) was from Eastman, Kodak Ltd.,
Kirkby, Liverpool, U.K.
The other materials were as follows:
Sephadex LH 20 was from Pharmacia Fine Chemicals,
Uppsala, Sweden. Precoated (Silicagel F 254) thin layer
chromatography plates xvere from Merck and chromatography
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paper was Whatman paper no. 1. Cellulose (Macrocrystalline
for thin layer chromatography) was from E. Merck, AG,
D«3TtSLstacit, Germany. Molecular sieve (aluminium sodium
silicate) type 4A was BDH Laboratory grade.
Solvents:
Light petroleum (b.p. 40 - 60°(2*), pyridine, hexane,
pentane were all BDH AnalaR grade and heptane vta.s BDH
o
laboratory grade. Light petroleum (b.p. 40 - 60 C),
AnalaR grade; propylene glycol (propane l,2,diol) and
iso octane (2,2,4 - trimethyl pentane) both general
purpose reagent grade were from Hopkins and Williams
Ltd., Chadwell Heath, Essex, U.K. Ethanol (Absolute
Alcohol B.P.) was from James Burrough Limited, 60
Montford Place, London S.E. 11. All the other organic
solvents, AnalaR grade, vjere obtained from BDH Chemicals
Ltd., Poole, Dorset, U.K.
Apparatus:
Hamilton syringes and barrels were from Hamilton, The
Hague, Holland. Eppendorf micro pipettes were purchased
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together with polypropylene tips from V.AC Howe Ltd.,
London. Cornwall automatic syringes were obtained from
Becton Dickinson and Co., Rutherford j\j o j.} U.S.A.,
The Heto Rotamix was manufactured by Birkerod
Denmark. The reciprocating shaker (Barra) and the
Multivortex mixer were from Baird and Tatlock,
Freshwater Road, Chadwell Heath, Essex, u.K.
Glassware:
The radioactively contaminated glassware was
soaked in a 5% solution of Decon (Decon Laboratories
Ltd., Ellen Street, Portslade, Brighton, U.K.) for
12 - 24 hv;;_;L,, then rinsed thoroughly in tap water and
deionised water and after soaking for a further 12 - 24
h>, -v. : in deionised double glass disti-lled water was dried
o
xn a hot axr oven at 100 Q. Other glassware was soaked
for 12 - 24 in a solution of Pyroneg (Diversey
Ltd., Cockfosters, Barnet, Herts.), after which it was
rinsed thoroughly in tap water, deionised water and





Preparation of Hemisuccinate and
Conjugation to BSA
Preparation of the hemisuccinate derivatives:
. f~reshly distilled and KOH-dried pyridine (15 W2d
was added to a mixture of lg of llc>^ -hydroxyprogesterone
(3 m moles) and lOg of succinic anhydride (30 m moles)
in a round bottomed flask containing washed antidumping
granules. The flask was connected to a reflttx condenser
fitted with a calcium chloride trap to prevent moisture
from entering the reaction flask. The contents of the
flask were refluxed on a sand bath for a period of
15 - 16 h' . The reaction mixture was then evaporated
under nitrogen under anhydrous conditions.
The dried semisolid residue was dissolved in 15 ml.
of ethylacetate and the succinic acid removed by washing
the organic layer 4 times with 8 ml. of water. The
organic extract was evaporated and a 20 mg portion of the
residue was checked by thin layer chromatography (TLC)
on silica gel in the solvent system ethylacetate:
methanol: acetic acid (90 : 7.5 : 2.5). This residue gave
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2 spots, one of Rf 0.4 and the other of Rf 0„6, corresponding
to the 11°<-hydroxyprogesterone marker.
The crude hemisuccinate preparation was purified
by dissolving in 15 ml. of ethyl acetate and extracting
with an equal volume of saturated NaHCO^ solution. The
bicarbonate extract was rapidly adjusted to pH4 with dilute
HCl to prevent hydrolysis of the 11«C -hydroxyprogesterone
hemisuccinate. The hemisuccinate was then extracted
back into ethyl acetate (15 ml) and evaporated to
dryness under nitrogen. A 20 mg portion of the residue
when checked in the TLC system (as above) gave a single
spot at Rf 0.4. The rest of this residue was dissolved
in a minimum volume of hot methanol and the hemisuccinate
crystallised by the addition of distilled water. After
recrystallisation from methanol by additi.on of water the
crystals were dried under vacuum and weighed. A yield of
35% was obtained.
A portion of the crystallised llK-hydroxyprogesterone
hemisuccinate was hydrolysed in in NaOH, extracted into
ethyl acetate and washed with water. The dry residue in the
above TLC system gave a single spot (Rf 0.6} corresponding
to llc^ -hydroxyprogesterone.
Preparation of 6 (3-hydroxyprogesterone hemisuccinate:
Ig of 6 P-hydroxyprogesterone (3m moles) and lOg
of succinic anhydride (30m moles) were refluxed in 15 ml.
of freshly distilled and dried pyridine for 8 h
The procedure for purification and crystallisation was the
same as above. The Rf of the starting material in the
above TLC system was 0.6 and that of the product 0.4.
Conjugation of llX -hydroxyprogesterone and 6 (3 -hydroxyprogesterone
hemisuccinates to bovine serum albumin (BSA):
The mixed anhydride reaction (Erlanger et al.,
1959) was used.
Procedure:
11<>( -hydroxyprogesterone-bovine serum albumin conjugate:
To a mixture of 50 mg (0.15 m mole) of llX -
hydroxyprogesterone hemisuccinate and 70j/J[ of
tri-n-butylamine (55.7 mg, 0.3 m mole) was added 2.5 ml. of
cold (4°c) dioxane, the reaction mixture being kept at 0°c.
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is/a of isobutyl chloroformate (17 mg, 0.15 m mole) was
then added. If a precipitate persisted a further sjJL
of isobutyl chloroformate was added. The reaction was
allowed to proceed for 30 min. . BSA (170 mg, 2.5^tmole),
dissolved in a mixture of 4.5 ml. water, 3.5 ml. dioxane
and 0.15 ml. NaOH, was then added while stirring, and
o
the reaction mixture was kept at O w and the pH maintained
at 8 by the addition of IM-tiaOH.
The reaction mixture was then dialysed against
running water overnight to remove the free steroids after
which it was adjusted to pH 4.6 with The
resulting precipitate was allowed to stand at 4°C
overnight and then centrifuged (2200g) at 4°C for 25
min . The residue was suspended in 5 - 10 ml. water
and the pH adjusted to 7.5 - 8 to dissolve the product.
Any free steroid was removed by precipitation with 8 ml.
of cold acetone and adjusting the pH to 4.5. The
precipitate was collected by centrifugation, resuspended in
water (5 - 10 ml) and dissolved by adjusting the pH to
7.5 - 8. The residual free steroid and other impurities
were removed by further acetone precipitation which was
carried out for a total of 4 times. Each of the
acetone extracts was evaporated, the residues dissolved- in
«►*
ethanol and scanned on an Unicam SP-800B spectrophotometer.
60
Under the conditions of investigation no steroid could be
detected in the last two acetone extracts.
The protein conjugate from the above procedure was
suspended in 8 ml. of water and dissolved by adjusting the
pH to about 8. Insoluble material was removed by centrifugation
(2200g) at 4°C for 25 min , the supernatant dialysed
against running water overnight and then lyophilized. The
yield of the conjugate was 115 mg.
Preparation of 6 8-hydroxyprogesterone-bovine serum albumin
conjugate:
55 mg 6 (3-Kydroxyprbgesterone hemisuccinate
(0.16 m mole) was reacted xvith 187 mg (2.7 mole) BSA
(molar ratio 1 : 60). The entire reaction procedure was




New Zealand white rabbits were selected for immunisation.
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Out of a total of 12 rabbits, 6 were immunised with
110<-hydroxyprogesterone-bovine serum albumin conjugate and
6 with 6 (3-hydroxyprogesterone-bovine serum albumin
conjugate. The animals were kept in standard conditions of
light and darkness.
(8 m<j)
N- ' The conjugate^was dissolved in 4 ml. of
0.9% saline and added to 4 ml. of FreundJs complete or
incomplete adjuvant. The two layers were thoroughly mixed
by a blade homogeniser (MSE) until a stable emulsion was
obtained. 0.1 ml. of the emulsion containing 1 mg. of
conjugate was injected into each rabbit subcutaneously at
4 sites, 2 over the scapuli and 2 in the thighs.
(b) Injection Schedule:
All the primary injections were administered in
Freund's complete adjuvant.
Immunisation of rabbits with 11^ -hydroxyprogesterone-BSA
conjugate:
All the booster injections of the conjugate were
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prepared in preund's incomplete adjuvant. After the 1st
booster the rabbits were divided into two groups for
further immunization.
In the first group, rabbits Rl, R2 and R3 were
boosted consecutively every 4§ to 5 weeks up to the 3rd
booster and were bled through the marginal ear vein 7-10
days after each injection. The rabbits were rested after
the 3rd booster for about 3 months before a 4th booster
was given. Rabbit R2 in this group was rejected after
the 4th booster because the antisera obtained after each
booster were consistently of low titres.
In the second group, rabbits R4, R5 and R6 were
boosted about every 10th week and were bled 7-10 days
after each booster. After the 3rd booster rabbit R6 died
and Rabbits R4 and R5 were rejected because of poor
titres of their antisera.
The two remaining rabbits Rl and R3 were rested for
about 3^ months before being given the 5th booster. Rabbit
r3 then died and the remaining rabbit Rl was further boosted
for the 6th, 7th and 8th times at intervals of 6, 20 and
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46 weeks respectively. The full immunization schedule of
the rabbits is given in Table i .
Immunization with 6 P-hydroxyprogesterone-BSA Conjugate:
The primary and all the booster injections of the
conjugate were administered in Freund's complete adjuvant.
The rabbits were divided into two groups for
immunization. Rabbits R 388, R 389 and R 391 were boosted
consecutively every 6 weeks - and bled 7-10 days later.
The other three rabbits R 379, R 390 and R 392 xvere boosted
every 12 weeks although they were bled every 6 weeks along
with the rabbits of the former group. The immunization
schedule over a 30 week period is shown in the Table 2
(c) Collection and Storage of Antisera:
The rabbits were bled by an incision of the marginal
ear vein, 50 ml. of blood from each animal being collected
at a time. The tubes containing the whole blood were left
at room temperature for 2 - 4 h and the resulting









































































































Male + M Female F
R 379 (0*) R 390 (<£)
R 392 (0)
Primary Injection No O No Primary Injection
1st Booster Yes 6 Yes 1st Booster
2nd Booster Yes 12 Yes
3rd Booster Yes 18 Yes 2nd Booster
4th Booster Yes 24 Yes
5th Booster Yes 30 Yes 3rd Booster
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rod. After this the blood was allowed to clot overnight
at 4°0. it was then oentrifuged at 2200g for 10 minutes
either at 4°£ or room temperature. The serum in the
supernatant was collected and decomplimented by heating
o
for 30 mm at 56 £.
Sodium azide, NaN was added as a bacteriostat
to each pool of antiserum to a final concentration of
0.1%. The serum was then divided into 2 ml. portions
in -glass containers and stored at -20°Q.
Radioactivity
Radioactive progesterone:
[ia<, 2o(- h] progesterone (specific radioactivity
r 3
53 Ci/m mole) and|l,2,6,7 - h] progesterone (specific
radioactivity 110 and 81 Ci/m mole) were stored in
dark brown bottles in redistilled ethanol at 4°Q at a
concentration of 10_/)Ci/ml. The tritiated tracers were
checked for homogeneity by |24rtitio7l chromatography on
a column of Sephadex LH 20. The solvent system used was
heptane-chloroform-ethanol (200 : 200 : 1 by vol.)
saturated with water (Murphy 1971).
Procedure:
lOg of the Sephadex LH 20 was swollen overnight
in the organic phase of the solvent system and used to
prepare a column of 31 cm x 0.9 cm (in glass columns
fitted with a sinter (No. one porosity)). The column was
washed with 200 ml of the organic phase before introducing
the radioactive steroid. 1 ml fractions were collected.
85 - 95% of the progesterone was recovered in fractions
10 - 15 (fig. 1). The radioactive steroid so recovered
was checked for homogeneity by TLC on silica gel in a
methylene chloride - acetone (80 : 20 by vol) solvent
system. The Rf was 0.6. It was also checked by paper
chromatography in the Bush A system [light petroleum -
methanol - water (100 ; 96 : 4 by vol)j . The Rf was
0.89.
For routine assays the radioactive progesterone
was used as supplied by the manufacturers although its




chromatography. The chromatographically purified and
unpurifiedj^njprogesterone was further compared by use in
standard curves.
Other radioactive steroids were used without further
purification.
Radioactive counting:
Samples were counted in a Tracerlab columatic 200
or a Packard Tricarb liquid scintillation spectrometer.
The tritiated progesterone to be counted was present in
aqueous solution. This was mixed with 10 ml. of liquid
scintillation fluid in counting vials which were then
shaken for 2 min to extract the tracer into the
organic phase. The radioactivity was counted without
f-separation of the two phases (Abraham et al 19711). The
o o
samples were counted at 4 (2. or 25 Q with a counting
efficiency of 50 - 55%. 10,000 counts for the counting
standards were collected which represented the amount of




Preparation of the covalently coupled antiserum:
1. Preparation of the activated microcrystalline cellulose:
[sg]
Macrocrystalline cellulose^was suspended in
distilled water to a final volume of 150 ml. Finely divided
solid cyanogen bromide was then added [3g/5g of cellulose]
while stirring. The pH of the suspension was maintained
between 10.5 - 11 by the continuous addition of 2M NaOH
until the reaction was complete as indicated by a constant
pH at 11o Small pieces of crushed ice were added
throughout the reaction to reduce the temperature. On
completion of the reaction about 250g of ice were added
and the mixture filtered on a sintered glass funnel. The
activated cellulose was rapidly washed with 2-5 X of cold
(4°C) 0„1M NaHCOSo This material was either coupled to
antiserum at once or dried by washing with increasing
concentration of acetone in water (500 ml of 50% then
70% acetone) and finally with acetone dried over a
molecular sieve. The residual acetone was evaporated
at room temperature and the dried active cellulose was
sealed in glass ampoules under dry nitrogen and stored
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at ~20°Co Under such conditions it was found to be stable
for many months.
2. coupling of antibody to the activated microcrystalline
cellulose
(yJ-QopJJ
Antiserum^was diluted to 2.5 ml with 0.1M
NaHC03, lg activated cellulose was added and mixture
rotated end over end at 4°C for 3 days. After coupling,
the solid preparation was washed essentially by the method
of wide (196,9). The solid was washed 3 times with
50 ml of 0.1M NaHC03 mixing for 20 rain at room
temperature for each wash. This was followed by a washing
in 50 ml of 0.2 M acetate buffer pH4 for 60 min after
which the solid was again suspended in the acetate buffer,
subjected to ultrasonic dispersal (Soniprobe, Dawe
Instruments Ltd. , London) for .10 sec , rotated
overnight or for 24 h and then centrifuged. This was
followed by 3 washes in 0.1M Nal-IC03 and a further two
washes rvith 0.05M sodium, phosphate buffer pH 7.5. Finally
the mixture was washed twice with 50 ml of the assay
diluent after which it was resuspended in the assay
diluent and stored at 4°(2 for use. Under these conditions
it was stable over a six month period.
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Development of Radioimmunoassay method
Assay Medium:
Selection of water for the assay:
A suitable water for the assay diluent was selected
from among the following:
(a) ordinary tap water
(b) deionised water
(c) sterilised water (autoclaved)
(d) double glass distilled water
(e) deionised double glass distilled xvater
The selection of the deionised double glass
distilled xvater as the more suitable for assay diluent was
made on the following basis: (1) a higher binding of [ h]
progesterone to the antiserum in the absence of unlabelled
progesterone xvas obtained when the assay buffer used for
the incubation mixtures xvas made from the double glass or
deionised double glass distilled water as compared xvith
that made from the other types of xvater. (2) 1 ml
aliquots (x 10) each of double glass and deionised double
glass distilled water samples were taken. These were
extracted in the light petroleum (the solvent used in the
method). The dried water extracts were then dissolved in
73
the respective diluent from the two types of water and
their responses were measured from the standard curves
prepared in the appropriate diluent. The apparent
response given by the two types of xvater extracts
(water blank) was minimal (less than 5g) or zero (same as
the O std.) in the extracts of the deionised double glass
distilled water as compared to double glass distilled water.
Buffers and the Assay Diluent
(1) Sodium salts Na^HFCM and NaH^P04 were used to
prepare the phosphate buffer [of 0.0M and pH 7.5].
The assay diluent was 0.05M phosphate buffer pH 7.5
containing gelatine (0.1%) to minimise the adsorption of
labelled and unlabelled progesterone to the glass
surfaces. A fresh batch of diluent was prepared every
o
week and stored at 4
(2) TRIS (hydroxymethyl) aminomethane was used to
prepare the TRIS-buffer 0.05M, pH 8.5.
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Solubility of progesterone in the diluent:
3
An ethanolic solution of [ h] progesterone containing
10, 100, and 600 pg progesterone was dispersed into glass
o t
tubes and taken to dryness under a streamj,nitrogen or air.
One ml diluent was then added and the tubes mixed
rapidly on a vortex mixer. Samples of the solution were
taken after 2, 5, 10, 15, 30 and 60 min and the
radioactive progesterone in solution measured. The
results are shown in Table 3 . It was found that 95%
or more of the [ h] progesterone was recovered from the
diluent in 2 minutes.
The preaddition to tubes (before the addition of
ethanolic [ Hj progesterone solutions) of 0.5 ml of a
5mg/ml solution of propylene glycol in methanol (Clark
and Gurpide 1972) did not improve the recoveries under
the conditions of the experiment (Table 3 ).
Separation systems :














































This was the previously optimised system (Hunterand Ganguli
1971) where the precipitation of the 1st antibody was
achieved by the addition of a donkey antirabbit ft-globulin
(NRS)
in the presence of carrier non-immune rabbit serum^. The
dilutions of NRS and DARS for assays were selected from
the flat plateau region of the precipitation curves.
After the primary incubation of antigen and antibody for
2 h , 50^£ each of NRS and DARS was added and the
tubes mixed after each addition. Complete precipitation
was obtained after incubation with the second antibody for
o Umi)
16 h at 4 C. • X>xluentJ(was then added before
centrifugation to minimize non-specific adsorption of
[ 3H] progesterone, and the tubes were centrifuged at
o
1500 x g for 45 min at 4 Q.. The timing of centrifugation
could be reduced to 15 min by the addition of talc
(1 mg/ml) to the diluent. The supernatent containing the
free fraction was counted. Using this system a separation
of 95% or more could be achieved in the presence of - -
excess of antibody and an apparent percent bound of 3 - 6%
(non-specific binding) in the absence of the antibody.
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(2) Separation of free and bound using covalently coupled
antiserum:
After the 90 min incubation of the antigen and
covalently-coupled antibody, 1 ml of diluent was added
and the free and bound fractions were separated by
centrifuging the tubes at 1500 x g for 10 - 25 min
at 4°C.
3
The non-specific binding of [ H] progesterone by
the solid phase was negligible. When covalently-coupled
non-immune rabbit serum was used instead of the antibody
3
the non-specific binding of [ H] progesterone to this was
below 3%.
Dilution Curves and Standard Curves:
1. Dilution Curves:
Serial doubling dilutions of the antisera were
made starting from an initial dilution of 1/500 of the
3
antiserum. After the addition of 10 pg of [ H] progesterone
(50Jj.Jl ) the tubes were incubated for 2 h (25°£) before
the separation of the free and bound fraction by double
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antibody. The same procedure was adopted for each solid-




Antisera dilutions that bound 70% or 50% of the [ h]
progesterone were selected from the dilution curves for
use in the standard curves. Standard curves included 4
zero standards (binding of [ h] progesterone to antibody
in the absence of unlabelled progesterone) and duplicate
progesterone standards containing 5, 10, 20, 40, 80,
160, 320, 640, 1280, 2560 pg amounts. Three non-specific
blanks were also taken which, when separating by the
double antibody method, did not contain the first
antibody. For the solid phase assay system the non¬
specific blanks contained excess of progesterone
(10 ng/ml) to saturate the antibody binding sites or,
alternatively, the non specific blanks contained
covalently-coupled non-immune rabbit serum instead of the
first antibody.
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(a) Double antibody system;
The tubes containing ethanolic progesterone
standards were dried under nitrogen or air. Diluent was
then added to all tubes and a time of 10 min was
allowed for progesterone to dissolve. This was followed
by the addition of [3H] progesterone (10 pg in 50) and
then the antiserum (50lit)- The tubes were incubated for
o
2 h at 25 q and the free and bound separated by the
addition of double antibody system.
(b) Solid phase;
The ratio of antiserum to cellulose was arranged so
that each assay tube would contain sufficient antiserum to
give 65 - 75% binding of the 10pg of tracer in an incubation
volume of 1 ml xvhen 50 - 100 Jj- g of solid-phase antiserum
was added. The tubes were incubated for 90 min on
a reciprocating shaker (170 - 200 strokes/ min ) and the
bound and free fraction separated by centrifugation.
(3) Progesterone standards from different sources were
compared using the antiserum to 11 c/ -hydroxyprogesterone-BSA
(Rl 4th booster) selected for the routine assay (Table 4 ).






































































































































The purity of the progesterone standards from different
sources was found to be similar as judged by the values for
the different points on the standard curve.
(4) Table 5 shows the effect of temperature and time
of incubation on the binding of 11$4-hydroxyprogesterone-BSA
3
antiserum (rl, 4th booster) to 1<^ , 2o( [ h] progesterone
in the absence and presence of 20, 80, 320 pg amounts of
unlabelled progesterone. From the values obtained
(Table 5 ) it appears that equilibrium is attained in
o o
30 mxn at 4 and 22 £• However, as the separation
of bound and free was achieved by the double antibody
separation it is not known whether the primary reaction
between antigen-antibody was stopped immediately on the
addition of the second antibody reagents. The
equilibrium was maintained over a 24 h " period.
Procedure for the antisera specificity experiments:
Stock solutions of steroids were made at a
concentration of 1 mg/ml in ethanoi. A suitable portion
was then diluted with the diluent to give a final
concentration of lljjig/ml (containing 0.1% ethanoi). All







































































































solutions were stored at 4°C and the solutions in diluent
were discarded after one week.
Procedure:
A maximum of 8 compounds were tested with 3 different
antisera in one experiment. For each steroid a range of
1 pg - lO^Jig was covered by serial 10 fold dilutions of the
starting concentration of ll^g/ml. Free and bound were
separated by double antibody system.
The percent cross-reaction was calculated as
described by Abraham (1969). It is expressed as the mass
of unlabelled steroid required to displace 50 per cent of the
bound tracer.
3
Mass of [ h] progesterone required to displace 50% = x
Mass of cross reacting steroid being displaced at
50% = Y
% cross-reaction = X/Y x 100
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Extraction by solvents:
A series of organic solvents xvere investigated for
extraction of progesterone from plasma as shown in the
Table 6 . These were the non-polar solvents heptane
(b.p„ 98°C„)) hexane (b.p. 65°C) and pentane (b.p. 38°£)
and light petroleum (b.p. 40 - 60°C). Diethyl ether
(b.p. 35°C), a relatively polar solvent, has been used for
extracting progesterone from plasma (Thorneycroft and
Stone 1972) and isoctane (b.p. 99°£) has been used to
elute progesterone from celite chromatography columns
i
(Abraham et al 19711). The selection of light petroleum
(b.p. 40 - 60°(?) as the solvent for extractd.on was based
on its low boiling range and low cost. It was also easily
available.
purification of light petroleum;
A mixture of light petroleum and concentrated 1^804
(100 : 10 by vol) was stirred for 4 - 14 h „ The acid
was separated and washing of solvent with further batches
of acid continued until the acid remained colourless after
6 h of stirring. The solvent was washed with NaHCO^
(0.2:1*1) to neutralise the acid then with deionised double
3
Table6Extractionof[H]progesteronefromplasmabydiffe entorg nicsolvent






































glass distilled water and was then dried over Na^S04 for 1-4
h .. The dry solvent was passed through a 45 cm x 0.4 cm
column of silica gel (800g) which had been heated at 100°['
overnight. The column was fitted with a sinter of zero
porosity. The purified solvent was washed twice with
deionised double glass distilled water, dried over Na2S04




To a portion of plasma (or water) ethanol was added
(10 vol. plasma + 1 vol. ethanol). After mixing on a Vortex
mixer the tubes were left standing for 10 min ,. Extraction
was carried out with 10 vol. or a minimum of 2 ml of light
petroleum (b.p. 40 - 60°C) for 2 min by hand on a Vortex
mixer or on a multivortex mixer which could mix simultaneously
one hundred 15 mm x 75 mm glass tubes (for volumes up to
200^4<£ plasma) or fifty 22 mm x 150 mm sized tubes (for volumes
above 200faH plasma) without stoppering. After extraction
the aqueous layer was frozen in a bath of solid CO^:
ethanol, the solvent extracts poured off and collected in
the glass assay tubes (15 mm x 75 mm). The solvent was
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evaporated under a stream of nitrogen or air in a heating
o
block at 60 and heated at this temperature for a further
20 - 30 mir<.
Urine: , \(0-5ir)l)
liquots of urine^collected during the follicular
or luteal phases of the menstrual cycle were extracted
with 10 vol. of light petroleum without the addition of




/) suspension of solid-coupled antiserum, 0'S5 "llj
(Rl, 4th booster) was added to the dried extract
residues at a concentration to bind about 70% of the
labelled tracer. 10 pg of [3h] progesterone in 50juH
of diluent was added to each tube and these were
incubated on a reciprocating shaker at 170 strokes/min
for 90 min . at 20 - BO*^ .
Assay Design and Quality Control:
[A.] All samples were assayed in duplicate. The plasma
volumes were selected in relation to their expected
progesterone responses on the standard curve. 500Ji£ ,
200Jj, 10- 100^1 portions were selected for measuring
levels in men or postmenopausal women, follicular phase
plasma and for luteal phase plasma respectively. The
plasma volume was made up to lOOjjjl with deionised double
glass distilled water.
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Two standard curves were set up with each assay,
one extracted and the other unextracted. To all tubes
of the extracted standard curve containing dry
ethanolic residues of progesterone standards a 200y(ii-
portion of deionised double-glass distilled water was
added. After mixing, the tubes xvere left standing for
10 min before extraction -with light petroleum by the
standard procedure.
The following controls were also included in
each assay:
(a) The recovery by the extraction procedure was
checked in quadruplicate. 200^$ aliquots of a male
plasma pool were added to dry ethanolic residues of
3
10 pg of [ H ] progesterone. The tubes were mixed and
left standing for 10 min before extraction. The
recovery of radioactivity in the extract was measured.
(b) The assay end-point recovery xvas checked by
adding unlabelled progesterone to plasma. 20oJxjt portions
of a male plasma pool were added to dry ethanolic residues
of 80, 160 and 640 pg of unlabelled progesterone. The
tubes were left standing for 10 min after mixing and
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were then extracted and assayed.
(c) A lOOjJ. portion of luteal phase plasma diluted with
male plasma was used as a quality control plasma. One
triplicate set of the quality control plasma was assayed
at the beginning and one triplicate set at the end of
each assay.
(4-6' >
(d) "Zero standard tubesj^were scattered throughout
the assay to monitor the binding of tracer to antibody
in the absence of unlabelled progesterone.
Urine
0.5 ml portions was taken for assaying progesterone
levels in follicular and luteal phase urines. 0.5 ml
portions of a pool of luteal phase urine were used as
quality controls. The rest of the assay design was




This was checked by comparing progesterone levels
in chromatographically purified and unpurified extracts
r
of plasma. 500<JxX portions of plasma from the follicular
phase, 50jJl portion of plasma from the luteal phase and
100Jxi of quality control plasma samples were each taken
in quadruplicate. 500Jjjt aliquots of follicular phase
plasma were also added to 4 tubes containing the dry
ethanolic residues of 500 pg of unlabelled progesterone
and to another 4 tubes containing similar residues of
100 pg of [l&C , 2i< -3h] progesterone to monitor the
recovery by the extraction procedure and the
chromatography procedure. After extraction,duplicate
samples from each category containing the dry residues
were chromatographed by Sephadex LH 20 chromatography
as described under the purification of radioactive
progesterone (P. 67 ) and fractions 10 - 15 (5 ml)
were collected. Portions of 5 ml eluate from a
separate column were added to each tube of the extracted




Quadruplicate 0.5 ml portions of the urine pools
from the follicular and from luteal phase were taken.
Another 0.5 ml portions of the follicular phase urine
were also added to 4 tubes containing dry residues of
unlabelled progesterone (500 pg) and also to other
4 tubes containing residues of 100 pg of 20<-
3
- Hj progesterone. These were chromatographed as above and
fractions 15 - 21 (6ml) were collected.
[ C ] Unextracted plasma:
The progesterone responses in extracted and
unextracted plasma samples using covalently coupled
11 c^-hydroxyprogesterone-BSA and 6 (3 -hydroxyprogesterone-BSA
antisera were compared as follows. For extracted samples
neat plasma was used whereas the unextracted samples
were assayed as (a) neat plasma (b) plasma diluted x 4
times (c) plasma diluted x 4 times, heated for 1 h
at 100°C, centrifuged (1500 x g) at 4°C for 10 min
and supernatant assayed. Plasma pools from males and
postmenopausal women were assayed at dose levels of
50JxjL , 100jjjl and 200jjl. volumes and those from luteal
phase and quality control pools were assayed at dose
levels of 20, 50, 100 and 200JxJ-. The incubation vol
of all tubes, including standard curves and extracted
samples, was first adjusted to 200hS- before the addition




Steroid antigens and conjugation
the bovine serum albumin (BSA).
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Formation of hemisuccinate derivatives of
llo<. -hydroxyprogesterone and 6 (3-hydroxyprogesterone (figs.2,3)
were confirmed by the following methods.
1. Infra red spectrum:
The spectra of the starting steroids and the products
are shown infigs.4,5 . The peak given by the carbonyl
group of the ester bond at 1733Cm ^ is present in the
products but not in the original steroids.
2. Nuclear Magnetic Resonance (NMR) spectra:
The maximum absorption of the starting materials
and their products were interpreted as shown in table 7
The evidence of hemisuccinate formation was obtained from
spectral shifts and the appearance of peaks of methylene
(CH2) groups and changes in the signal which are con¬
sistent with the expected substitutions at the
lip - and &X -positions.
3. Melting points (M.P.) and Thin Layer Chromatography (TLC):
The M.P. of 11»< -hydroxyprogesterone and.
6 p -hydroxyprogesterone were respectively 16Q°C_ and 165°(2
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Fig. 2
T.L.C. SYSTEM : A Ethyl Acetate : HeOH : Acetic Acid : B : Benzene : EtOK
90 7.5 2.5 4 1
11^-HYDROXY PROGESTERONE MR 160°
1K-HYDROXY PROGESTERONE HEM! SUCCINATE M R U8°
°c 7




6 hydroxy progesterone hem! succinate m.r 155°
T.L.C. SYSTEM : Benzene : Ethyl Alcohol : Ethylacetate : KEOH : Acetic Acid











Nuclear Magnetic Resonance Spectrum Analysis






C-18 methyl group 0.71 £ 0.69
C-19 methyl group 1.25 S 1.33 £
C-21 methyl group 2,09 <T 2.13 cT
C-ll-P-H 5.10 - 5.50 cf
as complex
multiolate
3.90 - 4.20 £as
sextet








C-18 methyl group 0.70 S Coeo
C-19 methyl group 1.38 <•> 1.29 <f
C-21 methyl group 2.12 £ 2.12 8
C-6~o< ~H 4.36 Sas
triplet
5.46 £





while those of their hemisuccinates were 148°(2 and 155°C-
Mobilities on TLC in the solvent system ethylacetate:
MeOH: acetic acid (180:15:5) were 0.4 for the hemisuccinates
and 0.6 for the starting material. Hydrolysis of the
crystals of the respective hemisuccinate preparations
yielded compounds with Rf values (0.6) similar to those
of the starting materials.
The general approach of making hemisuccinate
derivatives was taken from Erlanger et al. (1959) who
described a hemisuccinate preparation at the 2l position
of deoxycorticosterone. Using their ratios of steroid:,
succinic anhydride (1:3) and refluxing time of h
only a 10% yield was obtained. The yield was similarly
poor after refluxing for 24 h- . This may have been
due to the saturation of pyridine with moisture over
such a long period resulting in its inability to continue
to absorb the succinic acid formed during the reaction.
This may also have been the reason for the poor yields
(less than 10.0%) which resulted when the reactants
were left at room temperature for 3 - 35 days.
The reaction mixture ratios were therefore altered
to 1 : 10 (steroid-succinic anhydride) and the reaction
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carried out by refluxing for 4.5, 8.0 and 16 h
A reaction time of 16 h was found to give the highest
yield (35% as compared to 20 - 25%). The use of freshly
distilled pyridine was most crucial in obtaining high
yields.
As the 6 (3-position is nearer than the ll^C - to the
a 4
double bond at J_\^ -3 oxo position (allylic) it is more
reactive and therefore for the preparation of
6 (3 -hydroxyprogesterone hemisuccinate a shorter refluxing
time period of 8 h was arbitarily chosen (40% yield).
Conjugation of llo< -hydroxyprogesterone hemisuccinate
and 6 j3~hydroxyp:rogesterone hemisuccinate to bovine serum
albumin (BSA) was achieved by the mixed anhydride
reaction (Erlanger et si., 1959). After the conjugation
unreacted progesterone-derivative was separated and
removed from the progesterone-BSA conjugate by repeated
acetone washings and the removal of free progesterone
checked in the washings bytf.v. scanning as described under
methods.
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Formation of 11®^ -hydroxyprogesterone-BSA and
6 (3-hydroxyprogesterone-BSA conjugates was confirmed by
evidence obtained from ultra violet (u.v.) spectroscopy
as shown in figures 6 and 7 . judged on this
evidence, the substitution of steroid molecules
calculated on a molar basis were 18 steroid mols/mol BSA
for the 11^ -hydroxyprogesterone-BSA and 31 mols/mol BSA
for the 6 p-hydroxyprogesterone-BSA conjugate. As
progesterone absorbs strongly in the u.v. region because
A 4of the presence of the - 3 oxo structure it was not
considered necessary to monitor the conjugation by an
alternative method such as the addition of radioactive
progesterone to the conjugation mixture.
It has been suggested that steroid-protein conjugates
with molar ratios of less than 10 are not effective for
antibody production whereas a steroid:protein molar ratio
of 20:1 or above is most effective (Niswender and Midgley
1970). However no formal evidence correlating differences
in substitution ratios with differences in the titre,
avidity or specificity of antisera has been published.
Conjugation of 11c/ -hydroxyprogesterone and
6 p-hydroxyprogesterone derivatives to BSA has been achieved
Fig. 6
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CONJUGATE BY U.V. SPECTROSCOPY
WAVELENGTH MILLIMICRONS
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by using different conjugation procedures and the steroid/
protein substitution ratios obtained by these procedures
is shown in Table 8 . Conjugation of progesterone
derivatives to bovine serum albumin takes place through
formation of peptide bonds to the S-amino group of the
lysine residues. There are 59 lysine residues per BSA
molecule and one N-terminal amino acid - that is a total
of 60 free amino groups available for conjugation to the
steroid derivative (Erlanger et al. 1957). From Table
it appears that not more than two-thirds of the amino
groups are available for conjugate to the steroid. This
may be due to destruction of some of these groups during the
conjugation - reaction procedure, to some type of chemical
inhibition, or most likely to some of the -NH?~ groups
being rendered inaccessible because of the tertiary
structure of the protein molecule (Erlanger et al. 1957).
TABLE8
Conjugationf11<<-Hydroxyprogesteronederiv v st bovineserumalbuminydifferentprocedures
Derivativesofprogesteronem deat llc<-position
MethodofConjugation used
Substitutionrat progesteroneu l/ molBSA
Authors
llK.-Hydroxyprogesteronehemisuccinat I!11 11! It11 II11 II llo<-Hydroxyprogesteronechloro- carbonate
MixedAnhydri ereaction II! It1! 1!ItI II11 Carbodimideeaction Schotten-Baumann reaction
24mols/molBSA 18mols/molBSA 26mols/molBSA 20mols/molBSA 18mols/molBSA 28mols/molBSA 36mols/molBSA










6(3-Hydroxyprogesteronehemisuccina e 1!1 6PCarboxymethylpr gesterone 6PCarboxymethylpr gest rone Progesterone6-(carboxymethylene) thioether
i■—-
MixedAnhydri ereact on HIt 11t! I!11I Carbodimideeaction
28mols/molBSA 31mols/molBSA 35mols/molBSA 24mols/molBSA 30mols/molBSA







Primary injections of the conjugate were given in
Freund's complete adjuvant at four subcutaneous sites - two
in the inner aspects of the thighs and two over the scapuli.
Using this route several groups of lymph nodes are
sensitized and the responses are generally superior to
those obtained by other simple procedures involving the
intraperitoneal or intravenous routes (Hurji „• and Landon
1971)„ The dose of conjugate per rabbit has been kept at
1 mg for all injections.
Following the primary injections} booster injections
were given at the same sites either in Freund's complete
adjuvant (in the immunization of 6 p-hydroxyprogesterone
antisera) or in Freund's incomplete adjuvant (in case
of llo< -hydroxyprogesterone antisera). Although the
route of immunization was based on the previous experience
of the laboratory the advantage of boosting at the same
sites may be that greater concentrations of sensitized
cells are present as a result of primary injection at
these sites (Parker 1971).
The schedule used for the first 30 weeks of
immunization for the six rabbits immunized wi.th
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llo< -hydroxyprogesterone-BSA conjugate is shown in
("P- 111J
fig. 111 . After the primary injection in Freund's
complete adjuvant (FCA), booster injections in Freund's
incomplete adjuvant (FIA) were given to three rabbits
(Rl, R2 and R3) at intervals of 5-6 weeks up to the
third booster and the other three rabbits (R4, R5 and
R6) were boosted twice at intervals of 11 - 12 weeks.
A further booster was given to rabbits of both groups
after a rest of 12 - 15 weeks. Rabbits R2, R4 and. R5
were rejected for giving unacceptable titres and
Rabbit R6 died after 30 weeks. Rabbits Rl and R3 were
further boosted at the 46th week after which Rabbit R3
died. Rabbit Rl was further boosted at 52, 72 and
118 weeks and the results are shown in fig. 12 (p.122). The
immunization schedule for progesterone -6p immunised
rabbits covering a period of 34 weeks is shown in
CP. 113)
fig. • Three of these rabbits (R.388, R389 and
R391) were boosted at 5 - 6 weekly intervals and the
other three rabbits (R3'/9, R390 and R.392) were boosted
at 12 - 15 weekly intervals, the primary and booster
injections being given in Freund's complete adjuvant.
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The choice of identical sites for primary and
booster injections may not be important since other workers
have obtained satisfactory antibodies by purposely changing
the route of administration cf the immunogen for the
booster injection. For example, Thorneycroft and Stone
(1972) gave primary injections of progesterone-BSA conjugate
by the subcutaneous routes and booster injections either
by the subcutaneous or intravenous routes. Kutas et al.
(1972) gave primary injections in three front and three
back toe pads, the routes were changed to intraperitoneal
in the 2nd week, to intramuscular (4 different places)
in the 3rd week followed by subcutaneous booster injections.
The progesterone antisera produced by these above
procedures by Thorneycroft and Stone (1972) and Kutas et
al. (1972) respectively were of high sensitivity and good
titre o
In contrast to the present immunization schedule,
in almost all of the published radioimmuno assays of
progesterone (Abraham et a3.„ 1973^, Furuyama and Nugent
1971, Thorneycroft and Stone 1972, Kutas et al., 1972,
Spieler et al. 1972, De Villa et al., 1972, Yousseffnejadian
R
et al., 19721) antisera have been raised by giving weekly
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injections of conjugates in Freund's adjuvant for periods
up to 3 or 6 weeks. Antisera so produced by these workers,
except those by Thorneycroft and Stone (1972) and Kutas
et al„ (1972), are generally inferior in terms of titre
and sensitivity when compared to the antisera raised by
the present immunization schedule where the injections
have generally been spaced at 5 - 6 or 11 - 12 weekly
intervals.
Comparison of the present immunization schedule
with those of others with respect to the quality and
quantity of antibodies produced is difficult because
there are many variations in these immunization
procedures. The progesterone antisera raised by
Thorneycroft and Stone (1972) and Kutas et al (1972)
although raised by a different immunization procedure
are similar to the present antisera in terms of their
titre and sensitivity. The injection dose of 1 mg/rabbit
used by these workers is, however, the same as used in
the present procedure. The injection doses of
progesterone-BSA conjugate used by Spieler et al. (1972)
in their immunization procedure are higher than the
injection doses of all the other workers.. They injected
10 mg of conjugate/animal in FCA every week for 3 weeks
before giving booster injections of 1 mg/animal at
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monthly intervals. Although there were other variations in
their immunization procedure, (for example, they gave
primary injections in the foot pad and booster injections
through the marginal ear vein), the poor detection
limit (300 pg/ml) and lower titre (1/480) of their
antisera as compared with all the others in the published
studies was probably due to the high injection doses of
immunogens that they used. It has been shown that large
doses of immunogens have the capacity to induce tolerance
in those cells which contain, and can potentially secrete
high affinity antibodies. Such tolerance can prevent them
from further proliferation (Goidl et al., (1968)),
In contrast, low doses of conjugate have been shown
to be beneficial in eliciting antisera of high titre and
affinity especially when injected intradermally at
multiple sites. Thus 75-100^g of testosterone-3-
conjugate was adequate to elicit antibodies whose
9
affinities were of the order of 1.4 x 10 1/m with
titres ranging from 1/10000 - 1/60000 in 4-5 weeks
without further boosting (Vaitukaitis et al., 1971). The
authors could not distinguish whether their success was
due to the use of multiple sites and the intradermal
route or, to the minute concentrations of immunogen
Ill
injected. Lader et al. (1973) have compared the method of
multiple intradermal injection with that of the standard
sequential intramuscular injections in rabbits using 4
different immunogens (Thyroxine-BSA, Oestradiol-BSA,
Angiotension I and h-TsH). Similar doses of immunogens
were used for primary and booster injections, the rabbits
were bled at intervals throughout the immunization
schedule and antisera tested for titre and avidity. The
results obtained with both methods were comparable except
that slightly better titres were obtained with intradermal
inj ections. Maximum titres were obtained within 10
weeks after intradermal injections and remained unchanged
on boosting. Thus, as suggested by these authors and
by Hum (1974), the technique of multiple intradermal
injections is preferable if rapid antibody production from
limited amounts of immunogens is required.
SECTION 3
Results and Discussion
3. Titre and sensitivity of antisera.
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The titre of an antiserum is an arbitary term
which is used to indicate the amount of antiserum that
will bind a stated proportion of added antigen under
defined experimental conditions, i In fig. 8 a series of
dilution curves using 1, 10, 100 pg of labelled
progesterone and 1 ng of labelled and unlabelled progesterone
3
(900 pg of unlabelled progesterone + 100 pg of [ H ]
progesterone) have been plotted. Titre could be defined
as the dilution of antibody that will bind 50% of any
given concentration of the antigen. As shown in the
fig.8 the antiserum can clearly distinguish between the
concentrations of 100 pg and 1 ng shown by the 10 fold
displacement of the curves but fails to make a similar
distinction between 10 and 100 pg as the curves using
these dilutions are only a little over two dilutions
apart. This suggests that the effective sensitivity of
the assay using this antiserum lies somewhere between
10 - 100 pg. There is virtually no displacement of the
curves between 1 - 10 pg amounts suggesting a limit
imposed by the avidity of the antiserum for the
antigen. Titre can thus also be defined as that
dilution of an antiserum which binds some stated









unaffected by further decreasing the amount of antigen.
Considered in this way the definition of titre is
related to the avidity of the antibody for the tracer
antigen and it is by this definition that the titres of
the antisera have been described in this thesis. Some
examples of these dilution curves are shown in fig. 9 .
Each antiserum contains multiple or heterogenous
populations of antibodies that react with the antigen
with different affinities. The effective sensitivity
of an antiserum depends on those antibodies that react
with the highest energy at a suitable concentration.
The affinity constant or K value is a fundamental
property of antisera which dictates their sensitivity
potential in terms of molarity rather than the mass of
the antigen and is of value in comparing the properties
of various antisera. However, from the point of view
of radioimmunoassays it is arguable whether calculation
of the K values of antisera by the method of Scatchard
(1949) or by the Michaelis-Menton hyperbola (Odell et al.,
.1969) yields any other information that cannot be derived




DILUTION CURVES OF PROGESTERONE-6 {3-ANTISERA AFTER 1st BOOSTER
(10 pg 3H TRACER ADDED)
ANTISERUM DILUTION X iO3
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In the present work the affinity constants of
selected antisera have been calculated by a method based
on a concept, suggested by Odell et al., (1969), which is
similar to that used for the determination of the
Michaelis constants of enzymes. In this method a graph
of bound to total progesterone is plotted (fig,10 )
and the concentration of free progesterone at 50%
saturation of the antibody is the reciprocal (l/K)
of the affinity constant K. The K values so determined
depend on the concentration of antibody because with a
higher concentration of antiserum a less sensitive
standard curve will be obtained which would alter the
ratio of bound to total progesterone. The affinity
constants as calculated by the method of Scatchard are
also concentration dependent (Rosenberg and Notkins
1974). Thus the K values, calculated by either of the
raethods are dependent on the experimental concentration
of the antisera. Therefore to obtain the true K value
of an antiserum the experiment should be carried out with
the antiserum at an appropriately high dilution for




Progesterone - 6 /3-Antiserum
R-388 at '/50000 final dilation (5th Bleed)
TOTAL PROGESTERONE [T]
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Using the optimum dilutions of antisera and trace
quantities of tracer (10 pg) the K values (affinity
constants) of three 11^-hydroxyprogesterone-BSA
9 9
antisera were 3.15 x 10 , 3.77 x 10 (Rl and R3, 4th
9
booster respectively) and 3.92 x 10 (R6, 3rd booster)
XMo The affinity constants of the three selected
6(3 -hydroxyprogesterone-BSA antisera were
9 9
2.92 x 10 , 3.55 x 10 (R 388 and R 389, 5th booster)
9 rt
and 3.92 x 10 (R 390, 3rd booster) X-/M.
There is no unanimity on the definition of
sensitivity among theoreticians. Yalow and Berson (1969)
have defined the sensitivity and precision in terms of
the slope of the dose-response curve while Ekins (1969) is
of the opinion that both sensitivity and precision
depend not only on the slope but also on the errors
involved in the determination of points on the response
curve. According to Ekins (1970) while precision is
the ability of an assay system to distinguish between two
hormone concentrations at any point on the response
curve the term sensitivity may be used to restrict one
of these points to a zero amount or concentration.
According to this concept sensitivity or detection limit
is defined as the minimum amount of hormone that can be
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measured with acceptable precision. Defined as such it
is the lowest concentration of unlabelled antigen which
results in a significant change in the response variable,
that is, a change equivalent to the standard deviation
of the replicates of the zero standards multiplied
by a "significant" value of the Students t
(approximately 2) (Hunter and Greenwood 1964, Borth
1970, Feldman and Rodbard 1971). However, determination
of sensitivity in this manner requires an accumulation
of data gathered from several experiments for an accurate
estimation of the standard deviation and this is not
always practicable in routine assay work. An alternate
approach has been chosen in the present work whereby
antisera sensitivities have been compared by measuring
responses at a constant factor of a 10% fall in %
binding of the tracer. Measured in this manner
sensitivities have been arbitarily defined as that
concentration of standard progesterone (in units/ml
incubate) which depresses the binding of labelled
progesterone by 10% (Hunter 1971 and 1973). This
expedient assumes that the errors involved are unrelated
to the individual antisera and is valid for comparative
120
purposes in systems in xvhich the conditions (e.g.
mass of tracer, binding of tracer in the absence of
added unlabelled antigen) are identical in curves
being compared.
Effect of booster injection and time on the titre and
sensitivity of antisera:
The effects of booster injections and time on
the titre and sensitivity of antisera is shown in
figs.11,13 and 13. Fig. 11 and 13 shows the
immunization schedule of rabbits immunised with
11-hydroxyprogesterone-BSA and 6p-hydroxyprogesterone-BSA
conjugates over a 30 and 34 week period respectively
and fig. 12 shows the immunization schedule over longer
periods of 46 weeks (R3) and 120 weeks (Rl) in rabbits
immunized with 11-hydroxyprogesterone-BSA conjugates.
In the llo^-hydroxyprogesterone-BSA immunized
groups of rabbits maximum titres were obtained after
14 - 18 weeks. The titres in 6 P-hydroxyprogesterone-BSA
immunized groups were still rising when the immunization
was stopped at 34 weeks, the significant feature here
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All the rabbits were bled once every six weeks.
1. R333, 339 and 391 were boosted once every six weeks.
2. R379, 390 and 392 were boosted once every twelve weeks.
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rabbits were boosted.. Thus the titres of antisera from
rabbits - 379, 390 and 392 at weeks 12 and 24, when
they were not boosted, were comparable to the titres
from the other rabbits which were regularly boosted.
On the whole although titres of antisera tended to
improve on boosting the responses obtained were very
variable over the time period of the study. These
observations are in agreement with those of
Thorneycroft et al. (1970) and Hanning et al„, (1972)
who obtained variable titres in antisera from sheep
immunized with oestradiol-17 (3 conjugate over 10 months
and <5Lldosterone-BSA conjugate over 262 days respectively.
Abraham (1974) found that titres reached a plateau in
.6-8 months.
With respect to the effects of booster injections
and time on the sensitivities of antisera it was observed
that maximum sensitivities were obtained in the first
3§ - 4 months of immunization and remained more or less
constant thereafter throughout the immunization schedule.
This is in contrast to the studies of Abraham (1974)
who found a consistent rise in the sensitivities of
antisera over a 13 month period.
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In summary, from the small number of animals
studied, it appears that the effect of booster injections
and time on the titres of antisera are variable whereas
maximum sensitivities once attained are likely to remain
unaltered. Secondly, the effects of long rests between
booster injections does not confer an additional
advantage in terms of titre or sensitivity of antisera
over that of the 5-6 weekly injections. These
observations are in agreement with those of Lader et al.,
(1973) who raised antisera to insulin in guinea pigs by
subcutaneous injections and found comparable results in
terms of titre and affinity between the groups of animals
which were injected monthly and those rested for 4 months
at different times during the immunization procedure.
SECTION _3
Results and Discussion
Specificity of progesterone antisera.
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Cross reactions have been defined as the reactions
of a given antibody population with more than one antigen
(Little and Eisen 1969). In the present work the antisera
have been raised to the 11°^ -hydroxyprogesterone-bovine
serum albumin and 6 (3 -hydroxyprogesterone-bovine serum
albumin conjugates. The lloC -position is well removed
from the functional groups of progesterone and being -
in configuration, it is below the mean planar structure of
the progesterone molecule. Coupling to protein at this
position through a hemisuccinate group was likely to
minimise masking of the steroid by the protein. Coupling
at the 6 p-position had the disadvantage that the protein
moiety in the conjugate was on the same side as the
progesterone molecule and in spite of the relatively longer
hemisuccinate link some masking of the steroid moiety in
the conjugate was possible. Secondly, because the 6 (3-position
a 4
is near the -3 oxo structure, antisera raised to
conjugates linked, at the 6 |3-position were likely to give
higher cross reactions with those steroids or metabolites
that structurally differed from progesterone at or near
the 6- position. In this respect the selection of 6»<.or
7c>{ as link positions could have been more effective.
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Progesterone antisera have now been raised against conjugates
linked at the 6cK -position (Niswender 1973, Jones and
Mason 1974) and the 7^-position (Bauminger et al. 1973).
The compounds -hydroxyprogesterone and 7e>^-hydroxyprogesterone
were not commercially available when the present work was
started. However, judging by the varied specificities of
these antisera to steroids differing in structure from
progesterone at or near the 6c<- or 7o<. -positions
[ -fnesbi-s en. 33ol, 2.° -one,
, 5c< -pregnane-3 20-dione), these sites do not
appear to confer any additional advantage over the 6 (3-position.
Extensive specificity studies have been carried
out only on those antisera which have given the best
sensitivities and titres. During the specificity
experiments, the dose response curves of steroids that
cross react in the assay system were found to be non-
parallel to those of progesterone itself. Changes in the
structure of the cross-reacting steroids resulted not
only in the expected lateral displacement of such curves
but also in progressively diminishing slopes as their
relative cross-reactivity decreased. This is illustrated
in fig. 14 for 3 compounds 17-hydroxyprogesterone,





AMOUNT OF STEROID ADDED
Detailed dose-response curves for progesterone ( U )
and three cross-reacting steroids, 17-hydroxyprogesterone
(□ )3 androst-4-ene-3,17-dione ( S ) and Cortisol (O)
3
The responses are plotted with the binding of [ H] progesterone
tracer (lOpg in 1 ml final incubation volume) in the absence
of unlabelled progesterone as 100% bound [first point (© )
+ S.D. in the Figure] and non-specific binding controls as
0% bound. The response curves for the cross-reacting
compounds are not strictly parallel to that of progesterone
itself but show diminishing slopes as the degree of cross -
reactivity falls. Each point represents the mean of duplicate
tubes. About 70% of the tracer was bound in the absence
of unlabelled steroid.
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Cortisol gave relative potencies of 0.038, 0.018 and
0.011% while the figures for 17-hydroxyprogesterone
were 1.0, 0.83 and 0.61 respectively at 20, 50 and
CProfesteKone loo)
80% inhibition of tracer binding^ •The differences in
relative potencies which emerge by accepting the
responses at 20, 50 or 80% inhibition of tracer binding
on the cross-reaction curves of the majority of steroids
are small and detailed studies as well as high precision
are necessary to show the small deviations from
parallelism.
The observations in the present studies are in
agreement with the theoretically predicted studies of
Ekins (1968) and Rodbard (1970). According to these workers
the relative potency of the two compounds varies as a
function of the extent to xvhich the tracer ligand is
bound and parallel dose response curves between two
compounds are obtained only if they react with an
antibody with identical affinities.
The degree of cross reactivity of a given compound
cannot thus be fully represented by a single figure
expressing its relative potency since this differs
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throughout the response-curve. The general practice of
expressing relative potencies in terms of single ratios
from the intercept of their dose-response at 50%
inhibition (Abraham 1969) of tracer binding is not
strictly valid unless the responses are parallel, and
where they are not its use implies a specificity which
is better than can be achieved in practice at the upper
half of the response curve but which is less than can be
expected in its lower half. However, as these differences
in relative potencies at different points on the
response curves are small the general specificities of
the antisera may be represented at least in relative
terms at the 50% inhibition point and they have been so
calculated in the present studies and are set out in
Table 9 . However these values should not be taken to
be the true cross-reactions in the assay and should be
separately checked. This is especially necessary in
situations where progesterone secretion is low (in follicular-
phase; or in men) and the plasma responses in the assay are
limited to the upper part of the response curve because in
such situations steroids like Cortisol or 17 hydroxyprogesterone
can introduce non-specificity to the assay endpoint.
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Response curves over the range 1 pg - \QjU.g were
run on various cross-reacting steroids. 25 compounds have
been tested with antiserum Rl which was finally selected
for the progesterone assay. Antisera from rabbits
R3 and R6 were tested with 20 compounds and the selected
antisera from the 6 B-hydroxyprogesterone-BSA immunized
rabbits (R388, R389 and R390) were tested with 22 compounds.
Table 9 sets out the specificities of three
llc< -hydroxyprogesterone-BSA immunized and the three
6 (3 -hydroxyprogesterone-BSA antisera. The data is
derived from several experiments and the conditions
used have been set out in detail in Table 9 and were
identical with those used in the routine assay.
The data in Table 9 shows that the specificities of '
the three llfx-hydroxyprogesterone-BSA antisera were
remarkably similar to one another; those of
6 (3 -hydroxyprogesterone-BSA group of antisera although
different from the ,llo<, -hydroxyprogesterone-BSA immunized
group were again remarkably similar to one another.
Table 9
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Specificity studies on rabbit antise ra to 11«-hydroxypro aes tf-r one-
bovine serum albumin and 6|>-hy d roxy prpges te ror.e - bo v i r.e serum albumin conjugates
Steroids were dissolved in tbp assay diluent. Tubes with a maximum concentration of 10 pg/ml contained 1% (v/v)
ethanol and these were serially diluted down to a concentration of 1 pg/ml. Incubation was for 2 h and
separation was achieved by the double-antibody method. Responses were calculated at 50% inhibition of tracer
binding except for cholesterol, whose maximum displacement (10% at 10 pg/ml) was used.
Specificities of rabbit antisera Specificities of rabbit antisera
to 1 l**-hydro«yprogesterone-bovine to 6{J-hydroxyorogesterone-bovine

















Progesterone 100 100 100 100 100 100
1 lex-Hydroxy progesterone 31 33 36 9.3 9.1 12.0
1 lc<-Hydroxy progesterone-
hemisuccinate 78 69 49
- -
6{J-Hydroxy proges terone-
hemisuccin3 te - - - 69.0 83.0 82.0
1ip-Hydroxyprogesterone 12 4 14 1.7 0.8 3.3
11-Oxoprogesterone 15 12 16 4.0 5.3 3.3
fip-Hydroxyprogesterone 0.8 0.9 1.0 56.0 20.0 28.0
20«-Hydroxypregn-4-en-3-one 1.0 1.0 2.4 1.8 0.91 1.1
2CjJ-Hydroxyp regn-4-en-3-one 0.05 0.1 0.1 0.1 0.05 0.04
5»-Pregnane-3,20-dione 13 7.5 17 68.0 55.0 57.0
53-Pregnane-3,20-dione 7 17 7 18.0 14.0 20.0
17-Hydroxypregesterone 1.2 2.4 1.4 0.2 1.25 0.53
3K-Kydroxy-5p-pregnar.-20-one 0.2 0.2 0.4 0.5 0.15 0.4
5<*-Pregnane-3c<~20o-diol 0.0001 0.002 0.0003 -
- "
5«r P re g n a n e - 3ji - 20xx- d i o 1 0.003 0.03 0.003 -
-
5p-Pregnane-3&"2ac»tfdiol
(pregnanediol) 0.008 0.035 0.05 0.014 0.002 0.043
3p-Hydroxy-pregn-5-en-20-one 0.13 0.11 0.05 8.0 1.0 5.3
3S,17-Hydroxypregn-5-en-20-one
(17-Hydroxypregnenolone) 0.02 - - 0.01 0.003 0.01
11-Deoxycorticosterone 0.9 4.0 1.9 0.7 1.43 1.54
11-Deoxycortisol (compound S) 0.15 0.07 0.16 0.47 0.45 0.53
Cortisol 0.02 0.03 0.03 0.02 0.002 0.001
Corticosterone 0.43 - - 0.025 0.005 0.06
Cortisone 0.02 - - 0. 01 0.003 0.01
Androst-4-er.e-3,17-dione
(androstenedione) 0.02 0.09 0.03 0.09 0.27 0.08
3p-Hydroxyandrost-5-en-17-one
(dehydroepiandrosterone) 0.004 - - 0.025 0.01 0.01
Choiesterol 0.0004 0.0008 0.0007 0. CO 5 0.002 0.002
Cholic acid fat*,7c*, 12cx-trihydroxy
cho'anic acid] Not detected
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The specificities of the 11^ -hydroxyprogesterone-BSA
group of antisera was such that divergencies from the
structure of progesterone which were distal to the
conjugation site were equally well seen whether they
were present in the A or the D ring or on the C-21
side chain. Generally a single change in A ring
(pregnenolone), B ring (6 (3-hydroxyprogesterone) or
D ring (17-hydroxyprogesterone) produced an approximately
one-hundred fold loss in potency. Multiple changes in
the cross reacting steroid appeared to be essentially
additive in their effect. As expected, antisera to the
ll^C -hydroxyprogesterone-BSA conjugate showed relatively
little ability to detect changes in substituents at the
11- position. The overall specificity of these antisera
then, is such that substances likely to be present in
blood and extractable with progesterone by non-polar
solvents are so present at levels which would not be
expected to interfere in the assay for progesterone.
The antisera to 6 p-hydroxyprogesterone-BSA did
not detect well substituents at the 6- position and
changes close to this position. For example, these
antisera did not detect well the loss of the C-4 double
134
bond as in the case of 5p<. and 5 p pregnane -3 20-dione or
a shift in the double bond to the C-5 position and change
of 3 oxo to 3-OH as in the case of pregnenolone. In all
other respects their cross reactions are similar to those
of 11®<-hydroxyprogesterone-BSA immunized group of
antisera. Assays based upon these antisera would therefore
be more vulnerable to interference from pregnenolone and
metabolites of progesterone which embrace changes near
or at the 6-position. Conversely, the use of a conjugate
involving 6- position has not conferred a proportionate
improvement in specificity with respect to progesterone
derivatives which have small changes at the 11- position.
The overall picture therefore leads to a clear though not
overwhelming preference for the antisera to
11 o< -hydroxyprogesterone-BSQ..
Effect of Time and Booster Injections on the Specificity
of Antisera:
The effect of time and booster injections on the
specificity of antisera was studied on the selected
llc< -hydroxyprogesterone-BSA antisera after the 2nd
booster. Antisera from Rabbit 1 was studied using 7
bleeds up to the 8th booster over a period of 120 xveeks.
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Antisera from rabbit R3 was studied using 4 bleeds over
46 weeks and that from rabbit R6 was studied with 2
bleeds over 30 weeks. Cross reaction studies of these
different samples of antisera were performed with 8
selected steroids. The results are described in
Table 10 for rabbit Rl and in Tablell for rabbits
R3 and R6.
The results show that the specificities of all
antisera for compounds pregnenolone, Cortisol and
11-deoxy Cortisol remained essentially unaltered in
the three rabbits through the periods covered. Only
minor variations were seen in the specificities for
11 t<-hydroxyprogesterone, 11-deoxycorticosterone and
cholesterol. The specificity for 11 p-hydroxyprogesterone
decreased nearly three-fold after the 2nd booster but
then remained unchanged in all the three rabbits in the
subsequent immunizations. In the case of 17 hydroxy-
progesterone there was a minor decrease in specificity
after the 3rd booster, specificity then remaining
unaltered following all of the subsequent boosters.
1
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The overall figures for cross-reactions of various
steroids show that the specificities of antisera have
generally remained unaltered over successive boosters.
However, the number of animals studied is too small to
make generalizations on the effect of successive booster
injections on the specificity of antisera, and there are
no comparable studies on the stability of antiserum
specificity with time in the steroid radio immunoassay
literature. Odell et al. (1969) while studying the
effect of immunization on the specificity of antisera
to certain protein hormones found that the specificities
of antisera to IITSH and HCG were retained or improved
with increasing immunizations while that of antisera to
HFSH decreased after five immunizations. Abraham
(1974) has suggested that specificity of antisera (which
were raised in ewes) improves in the first 6-8
months with respect to steroids differing from the
immunogen at the site of linkage and that this period is
then followed by decreased specificity, whereas the
specificity of the antisera for steroids differing from
the immunogen at the distal position of the molecule
increases with the duration of immunization up to 12
months. For example, the specificity of antisera to
oestradiol-17-BSA with respect to oestrone and of
139
antisera to testosterone-3-BSA to -androstaiie
3 p-17 P-diol improved 2-3 fold in the first 6-8 months
and then decreased 4-5 fold afterwards over a 12 month
period. The specificity of testosterone-3-BSA with
respect to androstenedione (differing in structure at
ring D - distal to the link) continued to improve
(3-4 folds) up to 9 months (Abraham 1974). The author
has however warned against extrapolation of these studies
on antisera raised in ewes to other animal species.
In the present studies the above specificity
trend has not been noticed. Firstly, no steady
improvement in specificity of llcK.-hydroxyprogesterone-BSA
antisera with respect to 11 P-hydroxyprogesterone
(the steroid differing at the site of linkage) or any
steroid in the first 6-8 months was observed. Further,
there was no deterioration in specificity after 6-8
months as the specificity of Rl and R3 antisera to
11 p-hydroxyprogesterone remained essentially unaltered
over a period of 3*5to 27 months (2nd booster - 8th.
booster) and from 7 months to 11 months (4th booster -
5th booster) respectively. Secondly, specificity of the
1T^< -hydroxyprogesterone antisera with respect to steroids
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such as Cortisol, pregnenolone or androst-4-en- 3, 17-dione
(differing from the immunogen at either of the distal
ends of the molecule) has remained essentially unaltered
over the time period of the immunization schedule.
Although the present specificity studies were
performed with a small number of animals they do suggest
that once the production of a specific antiserum is
evoked this specificity is likely to be retained
following further booster injections. However, this
stability cannot be taken for granted and specificity




(a) Progesterone-like activity in urine.
(b) Behaviour of unextracted plasma in the assay.
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Extraction of progesterone from plasma by petroleum ether:
The choice of light petroleum A.nalaK grade from
BDH or H&W1, B.P. 40 - 6O°0) as the solvent for extracting
progesterone from plasma was based on the following:
non-polarity, low boiling range, low cost and easy
availability. The main disadvantage is that each batch
has to be checked for its suitability for the assay.
For this purpose the standard purification procedure for
hydrocarbons has been slightly modified and the details of
this procedure are given in the methods section.
The main problem when using light petroleum as the
extraction solvent was the variability of extraction
rates (70 - 90%) of the radioactive progesterone from
plasma. The addition of ethanol to plasma prior to the
extraction significantly reduced this variability, and the
recoveries of progesterone were markedly improved. The
results of these extraction recoveries after the addition
of ethanol 10% v + v (1 vol. ethanol + 10 vol. plasma) are
shown in Table 12 . A single extraction gave a mean of
92.4 +_ 1. 2 (SD) for 50J/.9-- 200$£plasma using 2 ml solvent
and extraction was quantitative if a second 10 vol. (2-7H10
142
r 3
Table 12 Extraction of [ H J progesterone from plasma by
light petroleum
3
Plasma was equilibrated with [ H] progesterone for 15 min.
at 20°C. Ethanol was then added to the plasma (10 vol.
plasma + vol. ethanol) and after a further 15 min. at
o
20 c the plasma was extracted with light petroleum.
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extraction was included. For the larger plasma
(50OUl),
volume^necessarily used when progesterone was to be measured
in men or post menopausal women, the single extraction
of 1 vol. x 10 vol. gave 91.5 + 0.7 (SD). For the routine
assay therefore ethanol (10% v + v) was added to the plasma.
After standing for 15 minutes the ethanolic plasma was
extracted with light petroleum, 2 ml of which was used for
plasma vols of 200 Jj>jL ox less and 5 ml for 50oJjtjlaliquots.
After extraction the aqueoitS layer was frozen by standing
the rack of tubes in solid CO^: ethanol, the organic layer
decanted into glass tubes 75 x 17 mm, evaporated to dryness
and the residue assayed in situ.
Effect of solvent residues on assay:
A series of experiments was carried out in order to
examine whether solvent residues produced by the above
procedure might distort the standard curve of the assay.
Progesterone was added over the range 5 pg - 10 ng in
ethanol solution which was then evaporated to dryness and
the residue redissolved in water (200^.£). Ethanol
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(10 vol. water + 1 vol. ethanol) was added and the
progesterone was then extracted into light petroleum
(2 ml), the aqueous phase frozen and the organic phase
decanted into the assay tubes. After evaporation, these
tubes were assayed together with similar standards which
were made up by adding the assay reagents (tracer and
antiserum) directly into tubes containing the residues
from the ethanolic solution of progesterone.
Fig. 15 (a, b, c, d) shows the two different ways in which
the solvent residues could distort the dose-response curve
of the standards. In each case the curve obtained for the
standards in diluent only is shown by open circles, and
those run in tubes containing solvent residues are shown
by the open triangles. Most batches of solvent yielded
curves of the kind shown in Fig. 15 (a). Two factors
appeared to be distorting the dose-response curve. In
Fig. 15 (b) the light petroleum had been purified as
described above, although some batches of solvent gave
curves of this kind without purification. The distortions
at this end of the curve were generally less severe in
solvent blanks than in water blanks. The remaining
perturbation which is seen at higher concentrations of
progesterone in Fig. 15 (a) was always seen when the
Fig. lf>(a) 145
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The legend for Fig. 15(a) and (b) is described on p. 146(a)
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Fig. 15(c)
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Fig. 15. Effect of solvent residues on the dose-response curve
In each case the curve with open circles represents a
standard curve in diluent. The curve with open triangles
represents the standard curve from tubes in which the dried
progesterone standards were redissolved in water (20Q^£)
and extracted with light petroleum by the standard extraction
procedure as described in the text. The first values on each
3
curve represent (+ S.D.) the percentage [ H] progesterone
tracer (10pg in 1 ml final incubation volume) bound in the
absence of unlabelled progesterone. All other values are
expressed as the means of duplicates. The four parts to
the Figure show the standard curve as (a) water-extracted
in impure solvent xvith drying of tubes at room temperature;
(b) water-extracted in purified solvent with drying of tubes
at room temperature; (c) water-extracted in incompletely
purified solvent but with drying of tubes under air at
60°C; (d) water-extracted in purified solvent with drying
o
of tubes under axr at 60 C.
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light petroleum was evaporated under a stream of N2°r aar
3
at room temperature. When assay diluent and then [ H]
progesterone was added to tubes containing these residues
only 70 - 85% of the tracer was removed when the aqueous
solution was decanted into counting vials. This was
presumably due to the presence of solvent contaminant
which dissolved some of the tracer and rendered it
unavailable to aqueous dissolution. This effect was only
slightly diminished by the solvent purification described
under methods (Fig.15 (b). However, it was completely
abolished (Fig. 15(C) by heating the residue to 60°C for
15 minutes under N^, or more conveniently by carrying out
the entire solvent evaporation process under N or air
at 60°(-» before addition of assay diluent. When purified
solvent was used and the evaporation temperature also
raised, the curve almost invariably was identical with
that obtained in diluent (Fig 15 d). Since distortions
caused by solvent residues can, if unrecognized, give rise
to both positive and negative artifacts, two standard
curves were run in all assays. One standard curve was
carried out without extracting the standards, these being
added, in ethanol, to the assay tubes, evaporated under
nitrogen and dissolved in diluent. In the second standard
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curve the standards were added in ethanol, evaporated to
dryness, the residues dissolved in 200^t$ of water and then
extracted with light petroleum after the addition of 20Jj.ji
of ethanol as in the standard extraction procedure. These
two standard curves have been superimposable in 7 out of
11 consecutive assays carried out over 13 weeks and using
four different batches of solvent. The remaining four
assays gave slightly displaced curves (similar to that
shown in Fig. 15(C) for the standards based on water
blanks and these, rather than the curve for standards in
diluent, were used to calculate the results of these assays.
Table 13 shows results for the recovery of
unlabelled progesterone added in different amounts over
the range 160 pg/ml to 12.8 ng/ml to portions from a pool
of male plasma from which different volumes were
extracted and assayed. By using a single extraction,
recoveries over the whole range of different amounts of
progesterone and of different plasma volumes of
91.4 + 8.6% (S.D„) were obtained, and two such extractions
over the plasma volume range 50 - 2Q0j/*l gave 96.8 6.6%
(ScD„). These findings confirm the high and constant




























































































recoveries obtained with [ H] -progesterone and provide
further evidence that the assay is free of distortion of
the plasma dose-response curve by solvent residues. The
absence of such distortion was further shown by the
finding (Table 14 ) that plasma samples containing high
concentrations of endogenous progesterone gave identical
concentrations when different volumes covering the entire
working range of the dose-response curve were extracted
and assayed. For reasons of practicality 2 ml of solvent
was used even when volumes below 200jxl of plasma were
being extracted. The fact that these gave values
identical with those found when 200of plasma was
extracted suggested also that no important interference
was produced by increasing the solvent/plasma ratio to
above the minimum of 10/1 regularly used.
Specificity of assay for plasma progesterone:
The specificity of the assay for measuring plasma
progesterone depends upon a combination of the specificity
of the assay end point and the selective nature of the
151
Table 14 Progesterone Concentration from varied volumes of plasma
Apparent plasma progesterone concentration (ng/ml) was
measured in samples from which varied portions were taken
and each was extracted with 2 ml of light petroleum.
Extraction was performed after the addition of ethanol to
plasma (10 vol. plasma + 1 vol. ethanol).
Vol. of plasma (^1) 10 50 100 150 200
Plasma no
1






6 29.4 29.2 28.0 29.7
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extraction procedure. The extraction of relevant steroids
using the routine procedure is shown in Table 15. in
women the plasma levels of 17-hydroxyprogesterone, 20^ -
hydroxypregn-4en-3-one, 3f3 -hydroxypregn-5-en-20-one
and androst-4-ene-3,17-dione can reach 2.2 ng/ml
(Youssefnejadian et al 1972 (p), 4 ng/ml (Florensa and
Sommerville, 1973), 2 ng/ml (Abraham et al, 1973) and
2 ng/ml (Judd and Yen, 1973), but such values are recorded
only during the mid-luteal phase and their equivalents at
the assay end. point (see Table 9 ) would amount
respectively to 26,40,3 and 0.4 pg of progesterone/ml
which would be insignificant at that time. In men and.
postmenopausal women the maximum concentration of
20c/ -hydroxypregn-4-en-3-one and 3 P-hydroxypregn-5-en-20~one
is about one-tenth of those found in the female luteal-phase,
so that here again they would not contribute more than
5% of the progesterone as measured. Also in men plasma
17-hydroxyprogesterone concentrations show a mean of
1.23 ng/ml, whereas the highest value reported was
3.2 ng/ml (Youssefnejadian et al 1972 [})• These would
give responses equivalent to 14.8 pg and 38. 4 pg apparent
progesterone/ml. As such they could represent, a small
153
Table 15 Extraction of H-labelled steroids from male plasma
by light petroleum (1 vol. plasma + 10 vol. light
petroleum) with and without prior addition of
ethanol to plasma
Samples of plasma (500 ul) were equilibrated with dried
3
H-labelled steroids for 1 hour and extraction with light
petroleum was performed 15 minutes after the addition of
ethanol (10 vol. plasma + 1 vol. ethanol). Four replicates




























intrusion into the assay's specificity, which should,
however, be generally acceptable since the mean recorded
value in men was 205 pg/ml.
The more polar adrenal steroids are poorly
extracted by light petroleum and as judged from the
extraction of Cortisol (Table 15 ) are likely to be
even less well extracted when ethanol is first added to
the plasma.
The specificity with respect to cholesterol was
further investigated. Samples from each of six
hypercholesterolaemic men and two post-menopausal women
whose plasma cholesterol concentrations ranged from
3.7 to 4.6 mg/ml and three with cholesterol concentrations
ranging from 0.87 to 1.0 mg/ml gave progesterone values
of 72-220 pg/ml, which were not different from those of
the normal group. Although this would suggest that the
specificity of the progesterone assay was maintained
because of poor extraction of cholesterol, direct evidence
from its measurement (Abell et al, 1952) in the light
petroleum extracts indicated that these contained almost
all of the total plasma cholesterol. This suggested that
the response obtained in the specificity studies
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represented in Table 9 and consisting of a small fall in
3
the percentage of [ H ] progesterone bound to antibody when
cholesterol was present at 10 Jjig/ml (which was at the limit
of its solubility in the diluent solution) did not represent
a true cross reaction.
Table 16 gives a list of certain steroids and
shows the effect of the combination of their specificity
and blood concentration on the present progesterone assay.
These steroids when present in their highest reported
concentrations under normal conditions or under stress,
contribute a total of 68.5 pg and 138 pg respectively
measured as progesterone and, as such, should interfere
in the assay especially when low levels of progesterone
are being measured. However, six aliquots each from
follicular-phase pool plasma (500//^), luteal-phase pool
plasma (50frfi) and a mixture of luteal-phase and male
plasma (100/jJ?) used as quality control for all assays,
were extracted by the routine procedure; in each case four
were assayed direct and the remainder were subjected to
gel filtration on Sephadex LH-20 using the solvent system
of Murphy (1971). The eluates having the elution
[3 ']
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gave mean values of 0.305, 14.0 and 3.0 ng/ml respectively,
while those measured directly gave means of 0.297, 14.0
and 2.82 ng/ml respectively. 20«Z-Hydroxypregn-4-en-3-one
and 17-hydroxyprogesterone, whose cross-reactions with the
progesterone antiserum contribute significantly to the
non-specificity in the assay (as shown in the Table 16 )
are clearly separated in the solvent system on the
Sephadex-LH 20 chromatography.
Precision of Assay:
The intra-assay precision was assessed by
calculating the coefficient of variation from the
duplicate determinations on 203 plasma samples, whose
values ranged from 85 pg to 35 ng/ml, which were assayed
in the ten consecutive assays whose standard curves are
represented in fig. 16 . using the formula, coefficient
of variation = /„ d
^ iqq)2 where d -/ x
_
2n
difference between duplicate estimations, x = mean of duplicate-
estimations and n = number of duplicate estimations, a
value of 9.7% was found. The inter-assay precision was
Fig. 16
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Radioimmunoassay standard curve for progesterone
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Mean (+ S.D.) obtained in 1 ml of final incubation volume
from ten consecutive routine assays.
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examined by calculating the coefficient of variation of
the means of triplicate determinations carried out on a
quality control pool in the ten consecutive assays. A
mean Value of 2.78 ng/ml was found and the coefficient of
variation was 5.0 %. In five of these assays the same pool
was assayed a second time (again in triplicate), the two
sets of tubes being placed at the beginning and end of the
assays. Mean values of 2.76 and 2.98 ng/ml respectively were
obtained.
Sensitivity and Working Range of the Routine Assay:
Sensitivity has been defined as that amount of
substance being assayed which gives a fall in percentage
binding of tracer of 2.5 x S.D. of percentage of tracer
bound in the absence of unlabelled progesterone (Borth
1970). Fig. 16 shows the mean standard curve (4- S.D.)
calculated from ten consecutive routine assays. The
sensitivity of the assay by the above formula is 11 pg/tube
for the routine 1 ml incubation mixture. However, the
slope of the standard curve is still shallow at the above
formal detection limit of 11 pg/ml and precision is
therefore less than optimal. It has been preferred
therefore to discard values derived from responses which
160
were 10% below the O standards that is, the binding of
tracer in the absence of unlabelled progesterone. When
considered in this way the working range for the routine
assay (with 1 ml incubation volumes) is 33 - 600 pg. This
provides for a range of 165 - 3000 pg/ml of plasma when
0.2 ml is extracted.
Assay of progesterone-like activity in urine:
Introduction:
Attempts to measure progesterone in urine began more
than 40 years ago when the occurrence of biologically
active "progesterone-like" material in urine was
reported (De Fremery et al„ 1931). Its identification
as progesterone using physio-chemical techniques, however,
was not proved even when extracts of 10,000 gallons of
human pregnancy urine was employed for this purpose
(MarkSr 1937). Progesterone remained unidentified in
urine even when more sensitive techniques like gas liquid
chromatography (GLC) were used for its measurement
(Drodowsky et al. 1965). After injection of radioactive
progesterone in a non-pregnant subject these workers
r
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isolated 0.01% of the radioactivity in the urinary
progesterone fraction. Ismail and Harkness (196*7)
isolated progesterone for the first time in a pooled human
pregnancy urine. The identity of their isolated compound-
as progesterone was based on its: behaviour in different
chromatographic systems; formation of specific chemical
products and the infra red spectrum. Later, the
isolation and identification of progesterone in the urine
of non-pregnant human subjects was reported by Van der
Molen and Corpechot (1968). They identified the isolated
compound as progesterone on the basis of: its specificity
of behaviour in 3 different column chromatography
systems and several paper chromatography systems; its
resistance to acetylation; the ability to reduce to
20 p-hydroxy steroid by the appropriate enzyme; the
behaviour of this reduced chloroacetylated compound in
and GLC systems; and finally
Rdjo
its crystallization to constant specific^activity with
20 P-hydroxyprogesterone-chloroacetate of the radioactive
compound which was isolated from the urine of subjects
after the intra-venous injection of radioactive
progesterone. On the basis of the injected radioactivity
they calculated a 24 h excretion rate of 0.05 -
0.5/t, g in the urine of non-pregnant women.
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With the availability of the present sensitive RIA
method for measuring progesterone in plasma it was of
interest to apply this method for the assay of progesterone
in urine of the normally menstruating women.
Dried petroleum ether extracts in duplicate from
follicular and luteal-phase urinary pools (0.5 ml
aliquots) xvere taken with another duplicate set of
follicular-phase aliquots containing uniabelled progesterone.
These were further subjected to sephadex LH-20 chromatography
purification and each fraction from these columns was
assayed by the standard radioimmunoassay procedure.
Radioactive progesterone was also added to the follicular
phase urine pool and the dried petroleum ether extract
containing the radioactivity was similarly purified on
Sephadex-LH-20 column. Fig. 17 shows the behaviour of
the progesterone-like activity in follicular and luteal
phase urinary extracts on the Sephadex LH-20 column. As
shown in the fig. 17 this progesterone-like activity in.
the two phases in urine behaves identically on the
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Fig. 18 shows the values obtained in 3 women from
24 h urinary samples collected daily throughout the
complete menstrual cycles. The ratios between luteal-phase
and follicular-phase excretion rates (4:1) are smaller
than the comparable ratios from plasma from the same
subjects (20:1). The urinary excretion rates of 4:1
were maintained when these assays were repeated using the
6 (3 -hydroxyprogesterone-BSA antiserum (R 390 5th bleed).
This discrepancy between follicular and luteal-
phase ratios in plasma and urine could probably be
explained on the basis of two factors: (1) that of the
non-specificity of the method in urine resulting in
contributions to the urinary progesterone values by
substances other than progesterone providing a base-line
showing false high, values which would be especially
noticeable in the follicular phase, or (2) that the
urinary excretion rate was disproportionately higher in
the follicular-phase. That the second explanation was
perhaps the more probable one was suggested by the
finding that the progesterone-like activity from pools of
follicular and luteal-phase urine samples which were
run on Sephadex-LH-20 columns (Murphy 1971) gave values




































































Mean urinary excretion (jf S.D) of progesterone-like
activity in 24h samples from three menstrual cycles
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hormone surge.
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of 0.479 and 1.78 ng/ml obtained following simple
petroleum ether extraction.
Behaviour of unextracted Plasma in the Assay:
In the course of this work it became apparent
that the specificities of progesterone antisera were
such as to be theoretically usable for assaying progesterone
in unextracted plasma. If all the compounds listed in
Table 9 were present together in plasma at their
maximum concentrations and exerted additive effects on
the specificity of the method then the progesterone
equivalent of their combined effect will be in the region
of 250 - 300 pg/ml (see also Table 16 }. Such a high
level of non-specificity would be unacceptable in
y
situations of low progesterone concentration as found in
follicular phase or in men, but it may be quite acceptable
in situations of high progesterone secretion such as,
for monitoring the presence and function of the corpus
luteum.
Assays were performed simultaneously on extracted and
unextracted plasmas using llo^ -hydroxyprogesterone-BSA and
167
6 p-hydroxyprogesterone-BSA antisera. Plasma pools so
assayed from (a) normal men (b) postmenopausal women
(c) lu teal-phase and (d), luteal-phase plasma diluted with
male plasma as quality control gave grossly high values
in unextracted plasma as shown in Table 17 and 18 .
Each pool of plasma was measured in differing aliquots
and the dose response curves for different quantities of
each pool were parallel to those of the progesterone
standards„ The high values in the unextracted plasma
remained essentially unaltered when plasma was diluted or
when the diluted plasma was heated for 60 min at
100°C,centrifuged and the supernatant assayed. The
latter procedure was adopted to inactivate the plasma
binding proteins and to free the plasma from lipids. As the
values in unextracted plasmas have remained essentially
unaltered by this treatment two possible sources of the
non specificity are suggested. One is that the binding
proteins were not inactivated and were competing with
the labelled progesterone (giving false low %B};
alternatively the high values might have been due to
other unidentified steroids or metabolites whose cross
reactions with these antisera were not tested.
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Table 17 Assay of Progesterone in Un-Extracted and Extracted










1 Neat Plasma n = 4
2 Plasma Diluted x 4
times
3 Plasma heated at
100 C centrifuged &

















Post Menopausal - Plasma Pool
1 Neat Plasma n = 4
2 Plasma Diluted x 4
times
3 Plasma heated at
100 C centrifuged & j -









Luteal Phase Plasma Pool
I
1 Neat Plasma n — 4 j13.75
2 plasma diluted x 4
times
3 Plasma heated, at
100 c centrifuged &
supernatent assayed n = 4
Quality Control Plasma Pool
1 Neat Plasma n - 4 10.25
Plasma diluted x 4
times
Plasma heated at
100 C centrifuged &



































Table 18 Assay of Progesterone in Un-Bxtraeted and Extracted Plasma
Pools Using Progesterone-6 3 BSA Antiserum
PROGESTERONE
ng/ml
in Unextracted Plasma Extracted
Male Plasma Pool
1 Neat plasma n-4
2 plasma diluted x 4
times
3 Plasma diluted x 4
times, heated at
0 '







































1 Neat plasma n = 4
2 Plasma diluted x 4
times
3 Plasma diluted x 4
times, heated at
O
100 C ;centrifuged &
supernatent assayed
Luteal Phase Plasma Pool
1 Neat plasma n = 4
2 Plasma diluted x 4
times
3 Plasma diluted x 4
times, heated at
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Applications of the plasma progesterone assay method:
The assay method has been applied to measure
plasma progesterone levels in certain steady state
situations and in some physiological studies.
Duplicate 0.5 ml aliquots of single samples from
each of 50 normal men were estimated and the progesterone
pp/wl
value found was 205 + 20.6 (SD)/. The value found for a
pool of plasma from 3 post menopausal women was 88 pg/ml.
1 Progesterone levels in the normal menstrual cycle:
Fig. 19 shows the mean (+ S.D.) of plasma
progesterone levels found from daily sampling throughout a
single menstrual cycle from 5 normal women, day 0 being the
centre of the midcycle plasma LH surge. The mean base
line levels in the follicular-phase was 332 pg/ml and a mean
luteal-phase peak of 14.6 + 3.7 (S.D,) ng/ml was found on
the 6th day after the LH peak. The progesterone values
obtained in the menstrual cycle and the values in men and
post menopausal women have been compared with the
previously published values by other radioimmuno assay














































Mean plasma progesterone concentration (+_ S.D„) in five
menstrual cycles.
Day O is the centre of the mid-cycle plasma luteinizing-
hormone surge.
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As shown in the table 9 progesterone levels in
the follicular-phase as reported by Abraham et al 1971,
De Villa et al 1972, and Kutas et al 1972, are higher than
antiserum raised to the 21-position of the 11-deoxycortisol
with a cross-reaction of 100% with progesterone„ In this
method progesterone is separated from other cross-
reacting steroids, except cholesterol with which the
antiserum cross reaction is reported at less than
0.01%, by chromatography on a Celite column. The high
values (545 + 103 pg/ml) as reported by these workers may
be due to the nonspecific intrusion from steroids not
tested in the system or from cholesterol whose plasma
concentration is nearly 10,000,000 times (2 mg/ml) that
of progesterone. The follicular-phase levels of
progesterone at 550 + 440 pg/ml (S.D.) for days 2 - 10
as reported by De Villa et al (1972) are difficult to
explain since the specificity of their assay end-point
was well tested and also the precision of their
measurement was good (with a inter and intra-assay
precision of 8%). They however did not test the cross-
reaction of their antiserum with cholesterol and it is
also likely that the majority of their samples (16
determinations) were from nearer day 10 when more mature
those reported by others. Abraham et al
Table19








180+63 (S.D,) 545+103 (S.D.)
265+192 (S.D.)
Women lutealng/ml8.56+4.73 _+6 phase(S.D,). *7daysbeforeovulation &7daysfterovulation
PlasmarogesteroneV luessRepo tedbyV riousAuthor Thorneycroft &Stone (1972) No 193 63-225 60-371 8.9 (4.3-19.4)DeVilla etal (1972) No 260+8 (S.D.) 260+8 (S.D.)Kutas etal. (S.D.)(1972) (plasma pools) No 195
Youssef- nejadian etal. (3-972/)"
a
Yes 230+6.8 (S.D.)
Cameron and Scaris- brick (1973)
Prese
Metho< No







follicles are present. Taking into account the good
sensitivity and specificity of the method the values of
follicular phase progesterone at 933 +86 (S.D.) as
reported by Kutas et al (1972) represents more probably
the periovulatory state of the follicle.
The mean luteal-phase values of 7.32 +- 4.26 (S.D.)
ng/ml as reported by the present method are comparable with
those of other methods.
As shown in fig. 19 the first significant rise in
plasma progesterone levels occurs on the day of the LH
peak and this is in agreement xvith majority of published
studies where the first rise in progesterone was observed
after the start of the LH surge (Johansson and Wide 1969,
Vandewiele et al., 1970, Abraham et al. 1972, Dupon et al.
1973). This observation is consistent with the presently




Progesterone is an intermediate in the biosynthesis
of adreno-cortical and gonadal hormones. However the
evidence so far suggests that it plays a minor role in
the biosynthesis of Cortisol in the adrenals. Its
function in females as one of the major secretory
products of the ovary is well established but the
evidence so far indicates that it plays only a minor
role in the synthesis of the main testicular androgens in
the male (see Chapter 1). The effect of stimulation and
supression of the adrenals on the circulating progesterone
levels in males was studied in collaboration with Dr„ A.
Toft of the Royal Infirmary, Edinburgh. The study of the
secretory pattern of progesterone in males was studied
in collaboration with the MRC Unit of Reproductive
Biology.
1, Effect of ACTH Stimulation on Progesterone Levels in Males:
Two normal male volunteers were given an
intramuscular dose of 1 mg of 1-18 -ACTH and samples
were taken every 15 min. from two hours before to four
hours after the ACTH administration.
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Plasma progesterone was measured in duplicate and
Table 20 gives their mean values for the ACTH stimulation
experimentsc After ACTH administration progesterone
levels showed the following pattern: a two-fold rise in
one subject (W) was observed after one hour, the rise in
levels going up to two and a half fold in 1,75 hours then
three-fold after 2.75 hours and remaining at these levels
up to four hours after the ACTH injection. In the other
subject (T) the progesterone concentration at one hour
after ACTH injection was up two-fold and after 1.5 hours
three-fold higher than basal levels. The progesterone
levels were four-fold at 3.0 hours then rose to six-fold
at 3,5 hours and remained at these levels at four hours
after the ACTH injection ivhen the blood sampling was
stopped.
The results show that the progesterone production is
increased as a result of ACTH stimulation and suggest the
ability of the adrenal cortex to synthesize progesterone
in response to ACTH stimulation. A four-fold rise in
progesterone concentration in response to continuous
infusion of ACTH has been previously reported (Strott
r4
et al, 19691). In the present studies the progesterone
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- 2 hours 199.0 270.0




- 1-25 175.0 220.0
- 1 hour 220.0 268.0
- Q-15 150.0 225.0
- 0-5^0 182.0 220.0
- 0-25 188.0 223.0
0 hour 208.0 225.0
+ 0<l<5 232.0 315.0
+ 0-5-0 256.0 525.0
+ 0-75 340.0 390.0
+ 1.00 hour 395.0 440.0
+ 1-25 400.0 590.0
+ 1-50 v, 480.0 615.0
+ 1-75 490.0 520.0
+ 2.00 hours 490.0 580.0
+ 2-25 , 490.0 385.0
+ 2-50 440.0 490.0
+ 2-75 700.0 640.0
+ 3.00 hours 555.0 860.0
+ 3-25 620.0 730.0
+ 3-50 570.0 1205.0
+ 3.75 , ■ 615.0 1030.0
+ 4.00 hours 640.0 1255.0
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levels were still rising up to four hours after being
stimulated with ACTH which has a short-life of 5-25 min(Besser etal3971
The slow rise in the progesterone levels may be due to the
intramuscularly administered slow acting synthetic
preparation of ACTH used or that it may suggest a slow
rate of synthesis of progesterone. This is also
suggested by the studies of Bermudez and Lipsett (1972)
who administered ACTH to five normal men by continuous
infusion and sampled the blood at frequent intervals.
It was shown that the levels of steroids of the z\5-
pathway, pregnenolone and 17-hydroxy pregnenolone increased
at a faster rate showing larger responses than that of
progesterone measured simultaneously indicating that
progesterone was not the important intermediate on
pathway in the synthesis of cortisol0 The present
studies thus support the results of the above workers
insofar as the slow synthesis of progesterone is concerned.
2. Effect of dexamethasone Suppression on the Progesterone
Levels in Men:
Two normal adult male volunteers were given 2 mg
dexamethasone every six hours starting at 11 p.m. Blood
samples were collected over a six hours period ten hours
after the first dose of dexamethasone and a single
sample was taken after 24 hours. The means of duplicate
determinations of progesterone levels on these samples
are shown in Table 21 . For this experiment the
appropriate controls and plasma samples taken before the
start of the dexamethasone test were not available so
the extent of reduction in the circulating levels of
progesterone following dexamethasone is not known. The
results in Table 21 show that significant concentrations
of progesterone are present following dexamethasone
suppression. The progesterone responses in the assay-
correspond to 12 - 15% inhibition of tracer binding and
therefore are clearly above the sensitivity limit of the
assay (10% inhibition of the tracer binding).
It has been suggested that progesterone levels in
males are mainly adrenal in origin as the production
rates in males and ovariectomised women are not
significantly different (kittle et al., 1966). It has
been shown that the high levels of progesterone in
children with congenital adrenal hyperplasia can be
suppressed by glucocorticoids (Strott et al., 1970)
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Table 21 Plasma Progesterone levels during
Dexamethasone suppression in Males




0.00 hour 167.0 140.0
+ O -V5 147.0 -
+ o-5 o 138.0 -
+ 1.00 182.0 108.0
+ 2.00 119.0 90.0
+ 3.00 90.0 97 o 0
+ o oo 90.0 131.0
+ 5 c00 117.0 117.0
+ 6.Q0 138.0 60.0
+ 24c00 209.0 90.0
Dose regimen: 2 mg dexamethasone at 2300 and 0600 hours
1 mg dexamethasone at 1200 hours and 6 hourly
thereafter
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suggesting that progesterone levels of adrenal origin are
under the control of ACTH. The measurable progesterone
response in the present studies after the suppression of
ACTH by dexamethasone can be explained as follows:
(a) A,s progesterone is not an important intermediate in
the synthesis of Cortisol, its levels (as shown in
Table 21 ) may reflect residual adrenal secretion which
is not suppressed by dexamethasone. (b) There may be
a testicular contribution to the circulating levels of
progesterone, but this is not likely to be significant
as progesterone concentrations have been shown to remain
unaffected in response to stimulation with HCG or after
suppression of the testis with fluoxymesterone (Strott
circulating levels of progesterone is under the control of
other pituitary hormones in addition to ACTH, the
progesterone response in the assay may represent a non¬
specific intrusion by cross reacting steroids. This
seems more likely because the responses as obtained are
limited in the upper part of the dose-response curve
where cross-reactions with steroids such as Cortisol, or
17 hydroxyprogesterone which is secreted by the testis,
(c) Lastly, unless a portion of the
because of their non-parallel curves, are more intrusive
than at the lower part of the response curve,
3. The Mode of Secretion of Progesterone in Males:
Recent evidence has suggested that some hormones are
secreted episodically rather than continuously, Cortisol
was the first steroid hormone shown to secrete episodically
(Weitzman et al., 1966). The secretion of luteinising
hormone (LH) has also been shown to be pulsatile in nature
(Santen and Bardin 1973), It was of interest to study the
pattern of secretion of progesterone and compare this
to the pattern of secretion of testosterone, LH and
follicular-stimulating hormone (FSH) to investigate their
relationships in the study of pituitary-gonadal axis
in males.
Progesterone levels xvere measured in blood samples
collected every 15 minutes over a six hour period from
three normal males. The plasma levels of LH and FSH were
measured by Dr. W.M. Hunter of the M.R,C. Radio Immuno
Assay Team and plasma testosterone levels were by Dr.
C. Corker of the M0R„C. Unit of Reproductive Biology,
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The pattern of secretion of LH, FSH, testosterone
and progesterone is shown in fig. 20 . The within assay
precision of duplicate measurements of progesterone
calculated as the coefficient of variation was 14.3%
(KM), 11.9% (RVS) and 10.0% (A) and the coefficient of
variation between duplicate determinations over the six
hour period in each subject was 25.3%, 26.8% and 25.9%
respectively suggesting that progesterone1 is not secreted at
a steady rate. However these results do not suggest a
regular pattern due to episodic secretion of progesterone.
The episodic manner of secretion of progesterone
could conceivably be involved in the gonadal or adrenal
steroid feedback control of pituitary hormones -
principally LH or ACTH. The present studies shown in
fig. 20 do not reveal any clear relationship in the
pattern of secretion between progesterone, testosterone,
LH or FSH. It has been proposed that a hormone is adrenal
in origin and under the control of ACTH if it is secreted
episodically and in synchrony with Cortisol (Katz et al.,
1972). Cortisol levels on these samples were not
measured however and they therefore provide no information
as to whether the variations in the secretory pattern of
progesterone are due to its adrenal component.
Fig. 20
Study of secretory tRTT^Rh of progesterone: /n mftccs in.
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GENERAL DISCUSSION
The cross-reaction studies with the three antisera
to 11^-hydroxyprogesterone-BSA (Table 9 ) show that the
degree of cross-reactivity found in sera from all of the
rabbits are similar to that first shown by Midgley and
Niswender (1970) and set out later in greater detail by
Niswender (1973). These studies thus confirm the
specificities that can be expected of antisera raised
to ll5^-hydroxyprogesterone-BSA conjugates. Generally,
described 1ft T^estnt uorK,
the specificities of the antiseraj^with respect to
3 P-hydroxypregn-5-en-20-one; 20 [3-hydroxypregn-4~ene-3~one ,
11-deoxycorticosterone and Cortisol are better than most
reported. • For 20<K -hydroxypregn-4-en-3-one two antisera
(Kutas et al., 1972, Niswender 1973) at 0.1% and 0.2%
cross reactions are better than the present 0.6 - 2.0%.
For 5 p-pregnane-3,20-dione cross-reactions of 5 - 7% with
most antisera and 17% with one (R3 4th booster) antiserum
compares favourably with reported values of 6% (De Villa
et al., 1972), 11% (Thorneycroft and Stone 1972) and
4.8% (Kutas et al., 1972). For 5^-pregnane-3,20-dione
cross-reactions are very varied in the present studies,
ranging from 7.5% (R3 4th booster) to 23% (Rl 7th and 8th
booster) and those reported range from 3.0% (Lindner et
186
al„, 1972), 5.4% (Spieler et al„, 1972), 6.5% (Kutas et
al., 1972), 13% (Niswender 1973), 15% (De Villa et al.,
1972) to 80% (Youssefnejadian et al., 1972).
Detailed specificity studies on antisera raised to
6 P-hydroxyprogesterone-BSA conjugates were also performed
(Table 9 ). These showed less ability to recognize the
loss of the double bond at C-4 position than was the case
with the 11^-hydroxyprogesterone antisera. For
5 P-pregnane~3,20~dione the cross-reactions were 18%
(R 388), 14% (R 389) and 20% (R 390) as compared with
the published figure of 8% (Jones and Mason 1974) and
100% (Lindner et al., 1972). For 5oC-pregnane-3,20~dione
the cross-reactions were 68% (R 388), 55% (R 389) and
57% (R 390) compared to reported values of 52% (Riley
et al., 1972), 100% (Lindner et al., 1972), 30% (Niswender
1973) and 67% (Jones and Mason 1974). As expected, the
changes close to the site of conjugation (at the 6 (3-position)
were not recognized by these antisera. Cross reactions
for 3 P-hydroxy-pregn-5-en-20-one by these antisera were
8% (R 388), 1% (R 389) and 5% (R 390) which are
comparable with figures of 8 - 14% (Lindner et al„, 1972),
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3% (Niswender 1973), 14% (Jones and Mason 1974) and better
than the reported figure of 68% (Riley et al, , 1972).
Since the plasma levels of pregnenolone are similar in the
follicular and luteal-phase (Abraham et al., 1973), the
limited specificity of 6 p-hydroxyprogesterone antisera with
respect to pregnenolone should still be adequate for
measuring progesterone levels to monitor the luteal
function. However, since they brought no compensatory
improvement in specificity with respect to other closely
related compounds which differ from progesterone elsewhere
in its structure, the 6 (3-hydroxyprogesterone-bovine serum
albumin antisera were discarded in favour of the
ll!>Chydroxyprogesterone~bovine serum albumin antisera
for the routine assay.
The chances of obtaining satisfactory antisera
using the present procedure of immunization may be judged,
from the following findings. The cross-reactivity of
eight key compounds was tested on each of six, four and
two different samples respectively from each of three
rabbits receiving lljK -hydroxyprogesterone-bovine serum
albumin conjugate over periods of 27, 11 and 7 months, and
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no significant alterations in specificity occurred., Six
of the total of 12 rabbits produced antisera which
permitted the establishment of assays of good sensitivity.
They did so within 3-6 months and once this quality was
achieved it was not later lost by any animal. Nine of the
12 rabbits gave antisera which could be used at final
dilutions of 1/20000 or more when their sensitivity
plateaus were first reached; eight of these animals later
gave antisera which were used at .1/40000 - 1/60000, and
again once reached such titres never subsequently
decreased to any significant extent. The titres obtained
by other workers have frequently been one order below this
range (Bodley et al., 1973; Spieler et al., 1972;
Kutas et al., 1972; Youssefriejadian et al., 1972) and the
improvement that has been obtained in the present
procedure may have been due to the widely placed time
intervals between the immunisation injections.
The two separation procedures used, the previously
optimised double-antibody system (Hunter aid. Ganguli 1971)and the
independently developed solid-phase antibody system., do
not disrupt the equilibrium established between the primary
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reaction with antibody and therefore the necessity for
investigating and optimizing a system for this particular
application to progesterone was obviated. The use of
solid-phase antiserum covalently linked to a solid
particular support medium (Wide 1969) seems ideal for
running routine assays of progesterone. The reagents
required are inexpensive, the activation and coupling
procedures are simple and no special optimization
is required for individual antisera, the losses in the
effective titres of antibody are small and there was no
loss of sensitivity when this system was used in place
of the double-antibody procedure (Bolton and Hunter 1973).
When stored at 4°C batches of covalently coupled antisera
were used for periods of up to 5 months without anyy
apparent change in properties. Activated cellulose was
also very stable if kept in ampoules under nitrogen. The use
of covalently coupled antiserum requires only one
centrifugation after the primary incubation giving a
high degree of precision suggesting that the "misclassification
«c&.
error" may be small (Rodbardj^l969). The single dis¬
advantage of having to use a shaker for continuous agitation
of the incubation mixtures can be obviated by the addition
1
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of sucrose or dextran to the incubation diluent as the
covalently coupled antiserum then remains in suspension
because of the increased density and viscosity of the
medium (Bolton et al., 1974).
The addition of ethanol to plasma before extracting
with light petroleum, as first suggested by Holmdahl and
Johansson (1972) for their competitive protein-binding
method, has yielded a sufficiently high and constant
extraction rate in a single extraction. This has removed
the necessity for using two extractions or the use of
[ H ] progesterone tracer to all individual plasma samples
in order to monitor and allow corrections for the variable
recovery rates obtained. The later procedure has been
used in the majority of published methods. It was
noticed that there were two ways in which the extracts
of plasma (or of water) could interfere in the assay and
this was investigated in detail since there is little
detailed evidence given in the literature about such
intrusion. A simple purification procedure for use on
unselected batches of light petroleum has been devised so
that the dependence on a closely defined source of light
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petroleum (e.g. see Johansson, 1969) has been made
unnecessary.
Of the previous reported assays based on the more
specific antibodies to lla£ -hydroxyprogesterone those of
Thorneycroft and Stone (1972), Kutas et al (1972) and
Cameron and Scarisbrick (1973) had sensitivities similar
to those found with the present antisera. The concentrations
and volumes of reagents used in the routine procedure
seems ideal for use in assaying progesterone in plasma
from xvomen of reproductive age. Thus, a 200portion
of plasma permits accurate measurement in the follicular-
phase and therefore provides for the detection of the
midcycle rise at its inception.
The theoretical specificity of the antisera to
the known steroids was such as to prompt investigation
into the possibility of assaying progesterone in
unextracted plasma. When assays were attempted on
unextracted plasma the values obtained were spuriously
high by about 2-5 ng of (apparent) progesterone/ml
while the total calculated contribution of known steroid
compounds to this response (about 300 Pg/ml) was much
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smaller. The interference seems unlikely to be due to
an effect on the separation system since neither the double
antibody nor the solid phase system used in these experiments
is distorted by differences in the amount of plasma present
in the incubation mixtures. The grossly high values
obtained in the assays of unextracted plasma could be due
to unidentified steroids or compounds with related
structures. However interference could also be due to
the non-specific inhibition of the primary antigen-
antibody reaction due to competition from progesterone-binding
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